	Recovered (N = 20)	Non-recovered (N = 21)	p-value

Age (ye	62.0 	67 (	0.860


Methods	Our algorithm	Traditional method

Computation time (s)	163	217

MSE	4.39 × 10-4	4.79 × 10-4


	Three weeks before treatment	Penultimate treatment day	Last treatment day	Reference data (n = 74 *)

Treated	2.72	2.67	2.99	2.43 ± 0.56

Control	3.09	2.09	2.69	2.43 ± 0.56


Diseases	BBB proteins and affected mechanisms

Alzheimer's disease	BBB disruption and permit peripheral IgG to brain. Decrease P-gp and accumulate amyloid-β in brain [67].

Parkinson's disease	BBB disruption increases therapeutic agent concentration and reduces efficacy of Pgp [6].

Stroke	Astrocytes secrete TGFβ that downregulates tissue plasminogen activator (tPA) and anticoagulant thrombomodulin (TM) [68].

Epilepsy	Transient BBB opening and upregulation of multiple drug resistance (MRD1) Pgp [69].

Trauma	Opening of BBB, release of IL-6 from astrocytes, and neuroinflammation [70].

HIV	BBB TJ disruption. Loss of glycoproteins and apoptosis of endothelial cell lead to increase diameter of cortical vessels [71].

Infectious processes	Increase CSF/serum albumin ratio. Bacterial lipopolysaccharides affect BBB TJ [72].

Brain tumours	Breakdown of BBB TJ, overexpress folate, insulin, and transferrin receptor, and downregulation of claudin 1/3 [73].

Ischaemic brain oedema	BBB breakdown due to MMP9 release by neutrophils and degradation of occludin, claudins, and JAM [74].


Variables	Characteristics	All (N = 1179)	Females (N = 486)	Males (N = 693)	Chi-square

 	 	n (%)	n (%)	n (%)	(p-value)

Age	Younger (≤ 22 years)	608 (51.6)	215 (44.0)	393 (56.9)	<.001

 	Older (> 22 years)	571 (48.4)	271 (56.0)	300 (43.1)

Role of religion while growing up	Major role of religion while growing up	736 (62.5)	334 (68.5)	402 (58.2)	<.001

 	Minor role of religion while growing up	443 (37.5)	154 (31.5)	289 (41.8)

Area of growing up	Urban	610 (51.7)	272 (56.0)	338 (48.8)	.009

 	Rural	569 (48.3)	214 (44.0)	355 (51.2)

Alcohol use in the last 12 months	Abstainers of alcohol	520 (46.8)	240 (54.3)	280 (41.9)	<.001

 	Seldom users of alcohol in last 12 months	450 (40.5)	163 (36.9)	287 (43)

 	Frequent users of alcohol in last 12 months	140 (12.6)	39 (8.8)	101 (15.1)

 	Missing	69	44	25

Alcohol use in relation to sexual activity*	Non-Use of alcohol in relation to sexual activity	391 (79)	146 (83.4)	245 (76.6)	.002

 	Use of alcohol in relation to sexual activity	104 (21)	29 (16.6)	75 (23.4)

 	Missing	95	27	68

Alcohol use at latest occasion of sexual intercourse*	Non-Use of alcohol at latest occasion of sexual intercourse	360 (72.9)	133 (76.9)	227 (70.7)	.001

 	Use of alcohol at latest occasion of sexual intercourse	134 (27.1)	40 (23.1)	94 (29.3)

 	Missing	96	29	67

Condom use with new partner	Consistent use of condom with new partner	603 (57.8)	216 (50.8)	387 (62.6)	<.001

 	Inconsistent condom use with new partner	440 (42.2)	209 (49.2)	231 (37.4)

 	Missing	136	61	75

Number of sexual partners in past 12 months	0-1 sexual partner in last 12 months	680 (66.4)	324 (77.5)	356 (58.5)	<.001

 	2 or more sexual partners in last 12 months	344 (33.6)	94 (22.4)	250 (41.3)

 	Missing	155	68	87

Variables	Characteristics	All (N = 1179)	Females (N = 486)

		n (%)	n (%)

Age	Younger (≤ 22 years)	608 (51.6)	215 (44.0)

	Older (> 22 years)	571 (48.4)	271 (56.0)

Role of religion while growing up	Major role of religion while growing up	736 (62.5)	334 (68.5)

	Minor role of religion while growing up	443 (37.5)	154 (31.5)

Area of growing up	Urban	610 (51.7)	272 (56.0)

	Rural	569 (48.3)	214 (44.0)

Alcohol use in the last 12 months	Abstainers of alcohol	520 (46.8)	240 (54.3)

	Seldom users of alcohol in last 12 months	450 (40.5)	163 (36.9)

	Frequent users of alcohol in last 12 months	140 (12.6)	39 (8.8)

	Missing	69	44

Alcohol use in relation to sexual activity*	Non-Use of alcohol in relation to sexual activity	391 (79)	146 (83.4)

	Use of alcohol in relation to sexual activity	104 (21)	29 (16.6)

	Missing	95	27

Alcohol use at latest occasion of sexual intercourse*	Non-Use of alcohol at latest occasion of sexual intercourse	360 (72.9)	133 (76.9)

	Use of alcohol at latest occasion of sexual intercourse	134 (27.1)	40 (23.1)

	Missing	96	29

Condom use with new partner	Consistent use of condom with new partner	603 (57.8)	216 (50.8)

	Inconsistent condom use with new partner	440 (42.2)	209 (49.2)

	Missing	136	61

Number of sexual partners in past 12 months	0-1 sexual partner in last 12 months	680 (66.4)	324 (77.5)

	2 or more sexual partners in last 12 months	344 (33.6)	94 (22.4)

	Missing	155	68


	Control group (N = 23)	CBT group (N = 25)	CBT with drink group (N = 24)

	Mea	S	Me	SD	M	SD	F-values


Device	Magnitude (%)	Phase (min)

Inductive voltage divider	0.0002	0.069

Shunt	0.01	0.3

DMM	0.01	0.583


		Cases(n)	Ref(n)	Odds ratio*	Confidence interval (95%)

Household economy

Non-poor	Close	68	317	Ref

	Remote	48	159	1.40	0.92 - 2.13

Poor	Close	10	41	Ref

	Remote	54	80	2.84	1.30 - 6.21

Mother's ethnicity

Kinh	Close	45	226	Ref

	Remote	23	104	1.30	0.75 - 2.28

Minority	Close	33	92	Ref

	Remote	79	135	1.61	0.99 - 2.62

Maternal education

Completed1° school (≥5 y)	Close	68	325	Ref

	Remote	46	165	0.84	0.86 - 2.01

Not completed1° school (<5 y)	Close	10	33	Ref

	Remote	54	73	2.59	1.16 - 5.82

		Cases(n)	Ref(n)

Household economy

Non-poor	Close	68	317

	Remote	48	159

Poor	Close	10	41

	Remote	54	80

Mother's ethnicity

Kinh	Close	45	226

	Remote	23	104

Minority	Close	33	92

	Remote	79	135

Maternal education

Completed1° school (≥5 y)	Close	68	325

	Remote	46	165

Not completed1° school (<5 y)	Close	10	33

	Remote	54	73


		Men	Women

		IHD mortality	Stroke mortality	IHD mortality	Stroke mortality

	Median	Age-adjusted HR	Multivariate HRa	Age-adjusted HR	Multivariate HRa	Age-adjusted HR	Multivariate HRa	Age-adjusted HR	Multivariate HRa

Cases (n)		1,308	1,142	454	370	596	500	317	261

Person-years subcohort (n)		17,057	15,017	17,426	15,017	20,512	18,241	20,512	18,241

Tap water characteristics


	n	Mean (SD) or %

Age	5052	46.0 (9.0)

Job seniority	4979	8.6 (7.1)

BMI

 Normal	2842	58.8%

 Overweight	1415	29.3%

 Obese	577	11.9%

Smoking	1776	35.5%

Physical workloada	4917	19.4 (9.7)

Leisure physical activity

 Sedentary	183	3.7%

 Light physical activity	2039	41.0%

 Moderate physical activity	2535	50.9%

 Vigorous physical activity	220	4.4%

Psychosocial work environmentb

 Emotional demands	5011	46.9 (17.9)

 Influence at work	5010	45.6 (20.0)

 Role clarity	5011	74.3 (14.2)

 Leadership quality	4931	57.2 (21.5)

Low back pain

 No pain	1558	31.2%

 Subchronic pain	2327	46.6%

 Chronic pain	1113	22.3%

Neck and shoulder pain

 No pain	1470	29.4%

 Subchronic pain	2113	42.2%

 Chronic pain	1423	28.4%

Knee pain

 No pain	3215	64.5%

 Subchronic pain	1166	23.4%

 Chronic pain	601	12.1%


	Astrocytoma	Medulloblastoma	Craniopharyngioma	Germ cell tumors	Ependymal tumours

Country	Author	Period	Age(yrs)

China		1990-2009	0-19	29.2%	13.1%	12.3%	8.1%	6.2%

Taipei	Wong et al. [11]	1975-2004	0-18	36.9%	15.8%	9.8	12.7%	6.8%

Japan	Makino et al. [12]	1989-2008	0-15	38.6%	13.1%	13.7	14.4%	5.2%


	Tiotropium	Control	Hazard ratio(tiotropium versus control)*(95% CI)

Time to first exacerbation, median month

Q1	19.4	14.6	0.80 (0.70 to 0.92)

Q2	22.4	13.6	0.83 (0.73 to 0.94)

Q3	16.6	16.3	0.97 (0.86 to 1.11)

Q4	14.9	12.7	0.88 (0.78 to 1.01)

Time t


Simulated Data	Mediated SEM	Mixed Model without Mediator

Effect Size	Effect Distribution	Effect	Bias (%)	Coverage Probability (%)	Power (%)	Bias (%)	Coverage Probability (%)	Power (%)

Large	Equal	Total	-0.8	94	100	-0.8	94	100

	Direct	Total	-0.8	94	100	-0.8	93	100

	Indirect	Total	0.9	94	100	-0.6	94	100

Medium	Equal	Total	-1.5	94	95	-1.5	93	94

	Direct	Total	-1.5	94	97	-1.5	93	96

	Indirect	Total	-1.3	94	93	-1.3	93	92

Medium-Small	Equal	Total	-2.0	94	80	-2.0	93	80

	Direct	Total	-0.9	94	84	-0.9	93	83

	Indirect	Total	-1.8	94	80	-1.8	93	79

Small	Equal	Total	-3.7	94	32	-3.7	93	32

	Direct	Total	-3.9	94	36	-4.0	93	35

	Indirect	Total	-3.7	94	34	-3.7	93	33

Simulated Data	Mediated SEM	Mixed Model without Mediator

	Indirect	Total	0.9	94	100	-0.6	94	100

Medium	Equal	Total	-1.5	94	95	-1.5	93	94

	Direct	Total	-1.5	94	97	-1.5	93	96

	Indirect	Total	-1.3	94	93	-1.3	93	92

Medium-Small	Equal	Total	-2.0	94	80	-2.0	93	80

	Direct	Total	-0.9	94	84	-0.9	93	83

	Indirect	Total	-1.8	94	80	-1.8	93	79

Small	Equal	Total	-3.7	94	32	-3.7	93	32

	Direct	Total	-3.9	94	36	-4.0	93	35

	Indirect	Total	-3.7	94	34	-3.7	93	33


Clinical parameter	Vehicle	SMI 6877002	Statistics

Incidence (%)	100	100

Survival (%)	100	100

AUC	10.6	8.7	P = 0.0804

Mean clinical score (day 13)	2.9	2.0	P = 0.1160

Mean day of onset	11.1	11.5	P = 0.4740

Mean peak disease severity	3.4	2.9	P = 0.0184

% Body weight loss (day 12 compared to day 0)	5.4	4.7	P = 0.2636

Clinical parameter	Vehicle	SMI 6877002	Statistics

AUC	10.6	8.7	P = 0.0804

Mean clinical score (day 13)	2.9	2.0	P = 0.1160

Mean day of onset	11.1	11.5	P = 0.4740

Mean peak disease severity	3.4	2.9	P = 0.0184

% Body weight loss (day 12 compared to day 0)	5.4	4.7	P = 0.2636


Industry (type of animal)	No. (%)

Campylobacteriosis	Cryptosporidiosis

Total	557 (100.0)	93 (100.0)

Animal production	380 (68.2)	73 (78.5)

(Cattle and other bovines)	271 (71.3)	63 (86.3)

(Chicken and other poultry)	35 (9.2)	0 (—)

(Swine)	21 (5.5)	0 (—)

(Other/Multiple farm animals)	53 (14.0)	10 (13.7)

Animal slaughtering and processing	91 (16.3)	5 (5.4)

(Beef cattle processing)	52 (57.1)	2 (40.0)

(Poultry processing)	13 (14.3)	0 (—)

(Swine processing)	10 (11.0)	2 (40.0)

(Multiple animals/Unspecified)	16 (17.6)	1 (20.0)

Veterinary services	24 (4.3)	7 (7.5)

Other (shelter, rescue, pet store)	62 (11.1)	8 (8.6)


Language	Number of Manual signs	Number of mouth gestures	% of signs accompanied by mouth gestures	Number of mouthings	% of signs accompanied by mouthings

British Sign Language	1552	539	35	560	36

Sign Language of the Netherlands	1162	458	39	299	26

Swedish Sign Language	1619	624	39	831	51

Number of Man	Number of	% of sig	Number	% of s

Language	ual signs	 mouth gestures	ns accompanied by mouth gestures	 of mouthings	igns accompanied by mouthings

British Sign Language	1552	539	35	560	36

Sign Language of the Netherlands	1162	458	39	299	26

Swedish Sign Language	1619	624	39	831	51


	RA control

	n = 35

Male/female	12/23

Age in years, mean ± SD	70.54 ± 10.84

Weight in kg, mean ± SD	53.32 ± 9.54

BMI, mean ± SD	21.79 ± 3.47

RA duration in years, mean ± SD	11.66 ± 12.52

MTX dose in mg/week, mean ± SD	-

TAC dose in mg/day, mean ± SD	-

Use of prednisolone, number (%) of patients	21 (60.0)

Prednisolone dose in mg/day, mean ± SD	6.06 ± 4.23

DAS28 (CRP), mean ± SD	2.79 ± 1.17

HAQ-DI, mean ± SD	0.85 ± 0.84

SDAI, mean ± SD	9.03 ± 6.32

CDAI, mean ± SD	7.83 ± 5.40

IP (%)	6 (17.1)

COPD (%)	3 (8.6)

Smoking history (%)	3 (8.6)


	Associative memory training group	Active control group

	Pre training M (SD)	Post training M (SD)	Effect size	Pre training M (SD)	Post training M (SD)	Effect size

Item memory	−0.19 (0.85)	0.29 (0.79)	0.58	−0.08 (0.70)	−0.04 (0.62)	0.06

Associative memory	−0.04 (0.70)	0.13 (0.59)	0.13	−0.13 (0.55)	−0.03 (0.81)	0.15

Spatial memory	−0.23 (0.68)	0.18 (0.55)	0.67	−0.07 (0.65)	−0.12 (0.76)	0.28

	Associative memory training group	Active control group

	Pre training M (SD)	Post training M (SD)	Effect size	Pre training M (SD)	Post training M (SD)	Effect size

Reasoning	−0.03 (0.73)	0.19 (0.87)	0.28	−0.20 (0.66)	−0.05 (0.64)	0.38


GO term ID	Functional area (GO term of category biological process)	No. of genes

GO:0033555	Multicellular organismal response to stress	2

GO:0070997	Neuron death	3

GO:0050877	Neurological system process	5

GO:0009991	Response to extracellular stimulus	5

GO:0007399	Nervous system development	6

GO:0071704	Organic substance metabolic process	11

GO:0016043	Cellular component organization	13

GO:0065007	Biological regulation	17

GO term ID	Functional area (GO term of category biological process)	No. of genes

GO:0033555	Multicellular organismal response to stress	2

GO:0070997	Neuron death	3

GO:0050877	Neurological system process	5

GO:0009991	Response to extracellular stimulus	5

GO:0	Ne	6

GO term ID	Functional area (GO term of category biological process)	No. of genes

007399	rvous system development

GO:0071704	Organic substance metabolic process	11

GO:0016043	Cellular component organization	13

GO:0065007	Biological regulation	17


Outcome over the last three months	ControlN=301	Brief adviceN=291	Coefficient/OR*95% CI

Weekly alcohol consumption (units)

Mean (SD)	20.3 (16.6)	18.1 (15.6)	−2.33

Median (IQR)	15.7 (8.3–29.9)	14.1 (6.5–25.1)	−4.69 to 0.03

Had unprotected sex (%)

No	123 (40.9)	137 (47.1)	0.89

Yes	178 (59.1)	154 (52.9)	0.63 to 1.25


Conditions	Reactor 1	Reactor 2

Carrier	Corncob	Concrete block

External carbon	No	Phase 1: no

Phase 2: yes (C/N = 2.5)

Phase 3: yes (C/N = 3.5)

Microbial test	Unused corncob	Unused concrete

Used corncob (surface)	Used concrete (surface)

Used corncob (core)	Used concrete (core)

Conditions	Reactor 1

Carrier	Corncob

External carbon	No

Microbial test	Unused corncob

Used corncob (surface)

Used corncob (core)

Reactor 2

Concrete block

Phase 1: no

Phase 2: yes (C/N = 2.5)

Phase 3: yes (C/N = 3.5)

Unused concrete

Used concrete (surface)

Used concrete (core)


Parameters	Chronic HBV patients	Health volunteers

No.	22	 20

Age (years)

 Mean ± SD	45.9 ± 8.1	38.5 ± 11.8*

 Median	46	36.5

 Range	30–61	25–58

Sex N(%)

 Male	17 (77.3)	14 (70)

 Female	05 (22.7)	6 (30)

Years from HBV diagnosis

 Mean ± SD	10.3 ± 1.6	NA

HBV DNA (log10 copies/ml)

 Mean	5.8	NA

 SD	0.2

ALT (U/L)

 Median	27.6	15.4*

 Range	10.1–445.6	5.6–37.5

AST (U/L)

 Median	26.8	11.3*

 Range	7.1–312.4	2.5–25.4

HbsAg (log 10 IU/ml)

 Median	1082.5	NA

 Range	90.0–12795.0


Program	Nucleotide	Exon	Gene

	Sensitivity	Specificity	Sensitivity	Sensitivity	Specificity	Sensitivity

Pair-wise GeneMapper	99.95	99.93	91.3	95.1	52.2	52.2

Multiple species GeneMapper	99.95	99.93	91.5	95.2	52.6	52.6


Variables	IS (n = 198)

Age (years, mean ± SD)	57.2 ± 11.8

Gender (%)

Male	122 (61.6)

Female	76 (38.4)

Hypertension (%)	119 (60.1)

Diabetes mellitus (%)	40 (20.2)

Hypercholesterolemia (%)	27 (13.6)

Hypertriglyceridemia (%)	56 (28.3)


	Mbeya	Mtwara	Mwanza

Health facilities (N = 18)	Non-HF AM providers (N = 38)a	Health facilities (N = 16)	Non-HF AM providers (N = 21)	Health facilities (N = 26)	Non-HF AM providers (N = 89)

N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)

% of outlets with anti-malarials in stock	18	100.0	38	100.0	16	100.0	20	95.2 (87.6–102.9)	26	100.0	81	91.0 (86.0–96.0)

% of outlets with RDTs in stock or microscopy	16	88.9 (76.7–101.1)	3	7.9 (0.7–15.1)	11	68.8 (49.7–87.8)	0	0.0	21	80.8 (68.1–935.)	1	1.2 (− 0.71–2.96)


Benign prostatic hyperplasia patients	n = 49

IPSS Score (Barry et al., 1992)

0–7	0

8–19	24

20–35	17

Unknown	8

Prostate cancer patients	n = 30

Gleason score (Epstein, 2010)

6 (3+3)	19

7 (3+4)	3

7 (4+3)	4

Unknown	4


Antibiotica	Minimal inhibitory concentration (μg/ml)b

	NVT2001S	ΔompK35	ΔompK36	ΔompK35/36

	NOc	LCP	NO	LCP	NO	LCP	NO	LCP

Aztreonam	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Ampicillin	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>	≥<underline>32</underline>

Piperacillin/TZB	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≤4

Cefazolin 	≤8	≤8	≤8	≤8	<underline>16</underline>	<underline>16</underline>	≥<underline>32</underline>	≥<underline>32</underline>

Cephalothin	≤8	≤8	≤8	≤8	<underline>16</underline>	<underline>16</underline>	≥<underline>32</underline>	≥<underline>32</underline>

Cefoxitin 	≤4	≤4	≤4	≤4	<underline>16</underline>	<underline>16</underline>	<underline>32</underline>	<underline>32</underline>

Ceftriaxone	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Cefpodoxime	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	0.5	0.5

Cefotaxime 	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25

Cefotaxime/CLA	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	0.25	0.25

Ceftazidime 	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	0.5	0.5

Ceftazidime/CLA	≤0.12	≤0.12	0.25	0.25	≤0.12	≤0.12	0.5	0.5

Cefepime	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Ciprofloxacin	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Gentamicin	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≤4

Antibiotica	Minimal inhibitory concentration (μg/ml)b

	NVT2001S	ΔompK35	ΔompK36	ΔompK35/36

	NOc	LCP	NO	LCP	NO	LCP	NO	LCP

Aztreonam	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Ampicillin	≥32	≥32	≥32	≥32	≥32	≥32	≥32	≥32

Piperacillin/TZB	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≤4

Cefazolin	≤8	≤8	≤8	≤8	16	16	≥32	≥32

Cephalothin	≤8	≤8	≤8	≤8	16	16	≥32	≥32

Cefoxitin	≤4	≤4	≤4	≤4	16	16	32	32

Ceftriaxone	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Cefpodoxime	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	0.5	0.5

Antibiotica	Minimal inhibitory concentration (μg/ml)b

	NVT2001S	ΔompK35	ΔompK36	ΔompK35/36

	NOc	LCP	NO	LCP	NO	LCP	NO	LCP

Cefotaxime	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25

Cefotaxime/CLA	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	≤0.12	0.25	0.25

Ceftazidime	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	≤0.25	0.5	0.5

Ceftazidime/CLA	≤0.12	≤0.12	0.25	0.25	≤0.12	≤0.12	0.5	0.5

Cefepime	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Ciprofloxacin	≤1	≤1	≤1	≤1	≤1	≤1	≤1	≤1

Gentamicin	≤4	≤4	≤4	≤4	≤4	≤4	≤4	≤4


	Swab	N

Score Card	Bacterial	Viral

Positive	21	19	40

	(True Positive)	(False Positive)

Negative	2	40	42

	(False Negative)	(True Negative)

N	23	59	82

	Swab

Score Card	Bacterial

Positive	21

	(True Positive)

Negative	2

	(False Negative)

N	23

Swab	N

Viral

19	40

(False Positive)

40	42

(True Negative)

59	82


Microbiology of prosthetic infection (1 day- > 1 year) after haernia or ventral mesh repair

Staphylococcus aureus	50–60 %

Staphylococcus spp	10–20 %

Enterococcus spp	10–20 %

Gram-neg	5–10 %

Pseudomonas, Streptococcus spp, Mycobacteria spp, mixed flora	rare

Microbiology of prosthetic infection (1 day- > 1 year) after haernia or ventral mesh repair

Staphylococcus aureus

Staphylococcus spp

Enterococcus spp

Gram-neg

Pseudomonas, Streptococcus spp, Mycobacteria spp, mixed flora

Microbiology of prosthetic infection (1 day- > 1 year) after haernia or ventral mesh repair

50–60 %

10–20 %

10–20 %

5–10 %

rare


Item #	VII. Monitoring, Evaluation, and Information Systems	Burkina Faso	Dominican Republic—national	Dominican Republic—subnational	Ghana	Mali	Total

		N	Score	N	Score	N	Score	N	Score	N	Score	N	Score

1.	Monitoring and evaluation of national HRH plan	16	5.1	22	4.5	14	5.4	16	4.8	22	5.1	90	5.0

2.	Monitoring and evaluation implementation capacity	16	4.7	23	4.8	15	5.6	16	4.6	24	4.4	94	4.8

3.	Use of data in HRH planning	18	5.2	22	4.4	15	4.6	16	4.9	24	5.3	95	4.9

4.	Staffing and employment information system	19	4.1	21	3.9	14	4.2	16	5.5	24	4.8	94	4.5

5.	Interoperability	16	4.1	22	4.4	12	4.7	15	3.9	19	5.1	84	4.4

6.	National health workforce registry	15	4.8	21	4.6	14	5.4	15	5.1	21	5.8	86	5.1

7.	Health worker licensure and registration system	16	5.3	22	5.0	15	6.4	17	7.6	20	4.6	90	5.8

8.	Information and communications technology infrastructure and capacity	18	3.8	23	4.9	16	5.8	18	4.4	25	5.0	100	4.8

Average respondents and scores	17	4.6	22	4.6	14	5.3	16	5.1	22	5.0	92	4.9

Item #	VII. Monitoring, Evaluation, and Information Systems	Burkina Faso	Dominican Republic—national	Dominican Republic—subnational	Ghana	Mali	Total

				N	Scor	N	Sc	N	Score	N	Score		Scor

		N	Score		e		ore					N	e

1.	Monitoring and evaluation of national HRH plan	16	5.1	22	4.5	14	5.4	16	4.8	22	5.1	90	5.0

2.	Monitoring and evaluation implementation capacity	16	4.7	23	4.8	15	5.6	16	4.6	24	4.4	94	4.8

3.	Use of data in HRH planning	18	5.2	22	4.4	15	4.6	16	4.9	24	5.3	95	4.9

4.	Staffing and employment information system	19	4.1	21	3.9	14	4.2	16	5.5	24	4.8	94	4.5

5.	Interoperability	16	4.1	22	4.4	12	4.7	15	3.9	19	5.1	84	4.4

6.	National health workforce registry	15	4.8	21	4.6	14	5.4	15	5.1	21	5.8	86	5.1

7.	Health worker licensure and registration system	16	5.3	22	5.0	15	6.4	17	7.6	20	4.6	90	5.8

8.	Information and communications technology infrastructure and capacity	18	3.8	23	4.9	16	5.8	18	4.4	25	5.0	100	4.8

Average respondents and scores	17	4.6	22	4.6	14	5.3	16	5.1	22	5.0	92	4.9


Variables	Results

Male, n (%)	20 (48.8)

Age, years	49.39 ± 0.82

Position, n (%)

 President of hospital	1 (2.4)

 Vice president of hospital	2 (4.9)

 Director of department	30 (73.2)

 Vice director of department	7 (17.1)

 No position	1 (2.4)

Title, n (%)

 Chief physician	35 (85.4)

 Vice-chief physician	6 (14.6)

Experience in the clinical work of digestive diseases, n (%)

 >20 years	33 (80.5)

 10–20 years	8 (19.5)

Grade of hospital, n (%)

 Tertiary, class A	35 (85.4)

 Tertiary, class B	5 (12.2)

 Second level, class A	1 (2.4)

Number of beds in the hospital, n (%)

 >1000	34 (82.9)

 800–1000	3 (7.3)

 500–800	3 (7.3)

 Others	1 (2.4)

Number of beds in the Department of Gastroenterology, n (%)

 >120	8 (19.5)

 80–120	10 (24.4)

 40–80	15 (36.6)

 Others	8 (19.5)

Number of patients with liver cirrhosis admitted to the Department of Gastroenterology every year, n (%)

 >200	19 (46.3)

 100–200	9 (22.0)

 50–100	13 (31.7)

Number of patients with liver cirrhosis and gastroesophageal varices admitted to the Department of Gastroenterology every year, n (%)

 >200	15 (36.6)

 100–200	7 (17.1)

 50–100	16 (39.0)

 Others	3 (7.3)

Variables

Male, n (%)

Age, years

Position, n (%)

President of hospital

Vice president of hospital

Director of department

Vice director of department

No position

Title, n (%)

Chief physician

Vice-chief physician

Experience in the clinical work of digestive diseases, n (%)

>20 years

10–20 years

Grade of hospital, n (%)

Tertiary, class A

Tertiary, class B

Second level, class A

Number of beds in the hospital, n (%)

>1000

800–1000

500–800

Others

Number of beds in the Department of Gastroenterology, n (%)

>120

80–120

40–80

Others

Number of patients with liver cirrhosis admitted to the Department of Gastroenterology every year, n (%)

>200

100–200

50–100

Number of patients with liver cirrhosis and gastroesophageal varices admitted to the Department of Gastroenterology every year, n (%)

>200

100–200

50–100

Others

Results

20 (48.8)

49.39 ± 0.82

Position, n (%)

1 (2.4)

2 (4.9)

30 (73.2)

7 (17.1)

1 (2.4)

Title, n (%)

35 (85.4)

6 (14.6)

Experience in the clinical work of digestive diseases, n (%)

33 (80.5)

8 (19.5)

Grade of hospital, n (%)

35 (85.4)

5 (12.2)

1 (2.4)

Number of beds in the hospital, n (%)

34 (82.9)

3 (7.3)

3 (7.3)

1 (2.4)

Number of beds in the Department of Gastroenterology, n (%)

8 (19.5)

10 (24.4)

15 (36.6)

8 (19.5)

Number of patients with liver cirrhosis admitted to the Department of Gastroenterology every year, n (%)

19 (46.3)

9 (22.0)

13 (31.7)

Number of patients with liver cirrhosis and gastroesophageal varices admitted to the Department of Gastroenterology every year, n (%)

15 (36.6)

7 (17.1)

16 (39.0)

3 (7.3)


Measure	Content validity 	Construct validity	Internal consistency	Interrater agreement 	Reliability 	Responsiveness

Cosmesis visual analog scale (VAS)	?	?	?	?	?	?

Disabilities of the arm, shoulder, and hand questionnaire (DASH)	+	+	+	+	+	+

Hand function visual analog scale (VAS)	?	?	?	?	?	?

Hand-specific ADL questionnaire	?	0	0	?	?	?

Michigan Hand Outcomes Questionnaire (MHQ)	+	+	+	+	+	+

Patient Evaluation Measure (PEM)	0	+	+	0	+	+

Patient-Rated Wrist Evaluation	+	+	+	0	+	+

Perceived grip strength scale	?	?	?	?	?	?

Scale of hand-specific activity performance	?	?	?	?	?	?

Measure	Content validity

Cosmesis visual analog scale (VAS)	?

Disabilities of the arm, shoulder, and hand questionnaire (DASH)	+

Hand function visual analog scale (VAS)	?

Hand-specific ADL questionnaire	?

Michigan Hand Outcomes Questionnaire (MHQ)	+

Patient Evaluation Measure (PEM)	0

Patient-Rated Wrist Evaluation	+

Perceived grip strength scale	?

Scale of hand-specific activity performance	?

Construct validity	Internal consistency	Interrater agreement	Reliability	Responsiveness

?	?	?	?	?

+	+	+	+	+

?	?	?	?	?

0	0	?	?	?

+	+	+	+	+

+	+	0	+	+

+	+	0	+	+

?	?	?	?	?

?	?	?	?	?


NAbs	OSEs	Properties/Functions

T15/E06	PC head-group of oxidized phosphatidylcholine	Blockage of OxLDL uptake by macrophages (Horkko et al., 1999; Binder et al., 2003)Binding to OxLDL and apoptotic cells and atherosclerotic lesions (Palinski et al., 1996; Chang et al., 1999, 2004)Inhibition of apoptotic cell/blebs mediated endothelial cell activation resulting in decreased monocyte adhesion (Huber et al., 2002; Chang et al., 2004)Inhibition OxPAPC-induced IL-6 secretion by lung tissue macrophage (Imai et al., 2008)Enhancement of in vivo apoptotic cell clearance in B cell-deficient (μMT) and sIgM-/- mice (Ogden et al., 2005; Chen et al., 2009a)Protection from atherosclerosis (Binder et al., 2003; Faria-Neto et al., 2006)Clinical score reduction in collagen induced arthritis (Chen et al., 2009a)

E014	Malondialdehyde	Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Palinski et al., 1996)Binding to apoptotic and cholesterol induced microvesicles (Huber et al., 2002; Liu et al., 2012)

NA-17	Malondialdehyde	Binding to OxLDL and apoptotic cells (Chou et al., 2009)Enhancement of clearance of apoptotic cells by macrophages in Rag1-/- mice in vivo (Chou et al., 2009)

LR01	Oxidized cardiolipin	Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Tuominen et al., 2006)

NAbs	OSEs	Properties/Functions

NA-17	Malondialdehyde	Binding to OxLDL and apoptotic cells (Chou et al., 2009)Enhancement of clearance of apoptotic cells by macrophages in Rag1-/- mice in vivo (Chou et al., 2009)

LR01	Oxidized cardiolipin	Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Tuominen et al., 2006)


Prevalence (%) in Control arm	Reduction in Prevalence due to each intervention (ECF or HH) individually	Prevalence (%) in ECF or HH arm	Overall number of communities needed (equally split into 4 arms)

k = 0.15

0.6	30%	0.42	24

0.8	30%	0.56	20

1.0	30%	0.7	18

1.0	20%	0.8	41

1.0	10%	0.9	168

Prevalence (%) in Control arm	Reduction in Prevalence due to each intervention (ECF or HH) individually	Prevalence (%) in ECF or HH arm	Overall number of communities needed (equally split into 4 arms)

k = 0.2

0.6	30%	0.42	30

0.8	30%	0.56	26

1.0	30%	0.7	24

1.0	20%	0.8	54

1.0	10%	0.9	227

k = 0.25

0.6	30%	0.42	45

0.8	30%	0.56	42

1.0	30%	0.7	39

1.0	20%	0.8	93

1.0	10%	0.9	398


Independent Variables **	Intercept	US-Born	SE	p value

α-Carotene	4.59	−1.03	0.21	<0.0001

β-Carotene	18.13	−3.27	0.84	0.0001

β-Cryptoxanthin	17.2	−3.79	0.75	<0.0001


Adverse events	All treated patients (n = 42)

Any grade	Grade 3–5a

Skin and subcutaneous tissue disorders

 Pruritus	6 (14.3)	0

 Maculopapular rash	6 (14.3)	0

 Vitiligo	3 (7.1)	0

 Skin hypopigmentation	2 (4.8)	0

 Dry skin	2 (4.8)	0

General disorders and administration site conditions

 Malaise	5 (11.9)	0

Endocrine disorders

 Hypothyroidism	4 (9.5)	0

 Hyperthyroidism	2 (4.8)	0

 Hypophysitis	2 (4.8)	1 (2.4)

Gastrointestinal disorders

 Diarrhea	3 (7.1)	0

 Nausea	2 (4.8)	0

 Abdominal pain	2 (4.8)	0

 Upper abdominal pain	2 (4.8)	0

 Colitis	2 (4.8)	1 (2.4)

Laboratory results

 Elevated AST	3 (7.1)	0

 Elevated eosinophil count	3 (7.1)	0

 Elevated ALT	2 (4.8)	0

Blood and lymphatic system disorders

 Anemia	2 (4.8)	2 (4.8)

Adverse events	All treated patients (n = 42)

Any grade

Skin and subcutaneous tissue disorders

Pruritus	6 (14.3)

Maculopapular rash	6 (14.3)

Vitiligo	3 (7.1)

Skin hypopigmentation	2 (4.8)

Dry skin	2 (4.8)

General disorders and administration site conditions

Malaise	5 (11.9)

Endocrine disorders

Hypothyroidism	4 (9.5)

Hyperthyroidism	2 (4.8)

Hypophysitis	2 (4.8)

Gastrointestinal disorders

Diarrhea	3 (7.1)

Nausea	2 (4.8)

Abdominal pain	2 (4.8)

Upper abdominal pain	2 (4.8)

Colitis	2 (4.8)

Laboratory results

Elevated AST	3 (7.1)

Elevated eosinophil count	3 (7.1)

Elevated ALT	2 (4.8)

Blood and lymphatic system disorders

Anemia	2 (4.8)

All treated patients (n = 42)

Grade 3–5a

Skin and subcutaneous tissue disorders

0

0

0

0

0

General disorders and administration site conditions

0

Endocrine disorders

0

0

1 (2.4)

Gastrointestinal disorders

0

0

0

0

1 (2.4)

Laboratory results

0

0

0

Blood and lymphatic system disorders

2 (4.8)


Probe/Chromosome	S.ita-Y1(c)	Qing 9(c)	S.adh-W94(c)	S.lac-W74(c)	S.par-W79(c)	S.pal-N193(c)	S.gla-W12(c)	S. are-N196(c)	S. pli-N195(c)

S. vir-Q24(p)	√	×	×*	×	×	×	×*	×	×

S. adh-W94(p)	×*	√	 	×	×	×	×*	×	×

S. gri-W8(p)	×*	 	×*	√	×	×	×	×	×

Qing 9(p)	 	 	√

S. gla-W12(p)	 	 	 	 	√	×	 	×	×

S. pli-N195(p)	 	 	 	 	 	√	 	×


Variables	No. of patients (n = 74)	Percentage (%)

Gender

Male	32	43.24

Female	42	56.76

Age (years)	54.36 ± 13.13	-

Hospital stay (days)	19.47 ± 10.19	-

Clinical presentation

Gastrointestinal hemorrhage	37	50.00

Abdominal pain	25	33.78

Palpable mass	5	6.76

othersa	7	9.46

Tumor location (portion)

First	17	22.97

Second	35	47.30

Third	12	16.22

Forth	10	13.51

Tumor size (cm)	5.08 ± 2.90	-

No. of mitosis

≤5/50 HPF	41	55.41

6–10/50 HPF	27	36.49

>10/50 HPF	6	8.10

Modified NIH risk classification

Low	32	43.24

Intermediate	8	10.81

High	34	45.96

Mutational analysis

KIT exon 11	9	12.16

KIT exon 9	3	4.05

NA	62	83.78

Preoperative imatinib therapy	1	1.35

Postoperative adjuvant therapy	16	21.62

Patients with emergency visit	5	6.76

Patients with metastases at diagnosis	2	2.70

Tumor recurrence or metastasis	19	25.68

Death case	14	18.92


	Placebo	1-day	3-day	7-day

Number of subjects	26	26	27	27

Age (years)*	41.0 ± 2.2	41.9 ± 2.2	38.5 ± 1.7	36.5 ± 1.4

Gende


Morbidity	Measuring instrument	Data source

Diagnoses	ICD-10 codes	chart review

Diseases	self-developed questionnaire	GP interview

	self-developed questionnaire	patient interview

	Four-Dimensional Symptom Questionnaire (4DSQ) [11]	patient interview

	Geriatric Depression Scale (GDS) [12]	patient interview

	Clinical Dementia Rating (CDR) [13]	rated by interviewer

Functional Status

Activities of daily living	Barthel Index [22]	patient interview

	Instrumental Activities of Daily Living (IADL) Scale [23]	patient interview

Motor skills	FFB-Mot [24]	patient interview

Vision and hearing	2 items rated on a 4 point scale	patient interview

Cognitive impairment	CERAD [25] subtests word list and animal naming	cognitive tests by interviewer

	Letter Digit Substitution Test (LDST) [26]	cognitive tests by interviewer

Pain	Graded Chronic Pain Scale (GCPS) [27]	patient interview

Health-related quality of life	EuroQoL (EQ-5D) Scale [28]	patient interview

Resources/Risk Factors

Physical risk factors	Body-Mass-Index and Waist-to-Hip-Ratio	physical checkup by GP

Physical activity	International Physical Activities Questionnaire (IPAQ) [29]	patient interview

Nutrition	12 items for frequency and portion size of nutriments	patient interview

Alcohol use	AUDIT-C [30]	patient interview

	total amount of alcohol consumption per week	patient interview

Smoking behavior	9 items indicating current smoking status and pack years	patient interview

General self-efficacy	General Self-efficacy Scale [31]	patient interview

Social support	F-SOZU K14 [32]	patient interview

Medical care	Patient Assessment of Chronic Illness Care (PACIC) [33]	patient interview at baseline

	age and gender of GP/size and location of surgery	GP interview

Utilization of medical services (incl. medication)	15 items (short form), respectively 91 items (long form)	patient interview

Sociodemographic Data

Age and gender	age and gender	chart review

Migrant status	standardised indicators for mapping migrant status [34]	patient interview at baseline

Marital status	marital status	patient interview

Living conditions	independent or assisted living	patient interview

Household size	household size/household members under 15 years	patient interview

Education	CASMIN classification [35]	patient interview at baseline

Former occupation	German epidemiological standard questionnaire [36]	patient interview at baseline

Income	household size adjusted net income	patient interview

Wealth	home ownership	patient interview


Noise receiving point	Noise at boundary of substation


Characteristics	Awareness (n)	x2	P – value	Percentage %

Sex

Male	51	1.03	0.31	43.2

Female	67			56.8

Age

18–29	8			6.8

30–39	22			18.6

40–49	42	31.58	p < 0.0001	35.6

50–59	20			16.9

60–69	10			22.0

Total	118			100

 Religious affiliation

Christian	109			92.4

Muslim	9	0.12	0.73	7.6

Total	118			100

 Educational status

None	21			17.8

Primary	35			29.7

Junior High School	50	20.37	p < 0.0001	42.4

Senior High School	10			8.5

Tertiary level	2			1.7

Total	118			100

Characteristics	Awareness (n)	x2	P – value	Percentage %

Christian	109			92.4

Muslim	9	0.12	0.73	7.6

Total	118			100

Educational status

None	21			17.8

Primary	35			29.7

Junior High School	50	20.37	p < 0.0001	42.4

Senior High School	10			8.5

Tertiary level	2			1.7

Total	118			100


Causes of deatha	All patients (n = 345)	Patients with primary GF (n = 22)	Patients without primary GF (n = 323)

Relapse	18 (5.2 %)	1 (4.5 %)	17 (5.3 %)

Infections	27 (7.8 %)	8 (36.4 %)	19 (5.9 %)


Primer (F: forward, R: reverse)	Sequence (5′–3′)	Product size (base pairs)	Description

fimA-F	CTAAATCCGCCGATCAAA	193	Type-1 fimbrial gene

fimA-R	GAGGAGACAGCCAGCAAA	193	Type-1 fimbrial gene

fimZ-F	GACGAACACCCTATTGTAAGA	202	Type-1 fimbrial gene

fimZ-R	GTTCCTGGATAGATTTGATTC	202	Type-1 fimbrial gene

flhD-F	GCATACATCCGAGTTGCTAA	237	Flagellar gene

flhD-R	TGAGTCAAACGGGTGATC	237	Flagellar gene

fliZ-F	GGAATATGTCGTGCGTTTA	221	Flagellar gene

fliZ-R	TATCAGAACTGGCGGTAAA	221	Flagellar gene

invF-F	TGAGAATGCTGGGAGAAGAC	194	SPI-1 gene

invF-R	AAAATGTGAAGGCGATGAGT	194	SPI-1 gene

sseB-F	AACGTGCCAGAAATACCCAG	199	SPI-2 gene

sseB-R	CCTTTATCCAGCTTCCCATG	199	SPI-2 gene

16S-F	TTCCTCCAGATCTCTACGCA	552	Housekeeping gene 16S

16S-R	GTGGCTAATACCGCATAACG	552	Housekeeping gene 16S

Primer (F: forward, R: reverse)	Sequence (5′–3′)	Product size (base pairs)	Description

fimZ-F	GACGAACACCCTATTGTAAGA	202	Type-1 fimbrial gene

fimZ-R	GTTCCTGGATAGATTTGATTC	202	Type-1 fimbrial gene

flhD-F	GCATACATCCGAGTTGCTAA	237	Flagellar gene

flhD-R	TGAGTCAAACGGGTGATC	237	Flagellar gene

fliZ-F	GGAATATGTCGTGCGTTTA	221	Flagellar gene

fliZ-R	TATCAGAACTGGCGGTAAA	221	Flagellar gene

invF-F	TGAGAATGCTGGGAGAAGAC	194	SPI-1 gene

invF-R	AAAATGTGAAGGCGATGAGT	194	SPI-1 gene

sseB-F	AACGTGCCAGAAATACCCAG	199	SPI-2 gene

sseB-R	CCTTTATCCAGCTTCCCATG	199	SPI-2 gene

16S-F	TTCCTCCAGATCTCTACGCA	552	Housekeeping gene 16S

16S-R	GTGGCTAATACCGCATAACG	552	Housekeeping gene 16S


Stages	R1	R2	R3	R4	R5	R6	R7

Pre-processing of each view (normal calculation, format conversion, etc.)	5 m	4m30s	4m	3m30s	3m	2m30s	2m

Definition of the ortho-image from the 3D model	2m	1m47s	1m35s	1m23s	1m13s	1m2s	45s

Definition of corresponding pairs between the model and the external image	3m	3m10s	3m20s	3m30s	3m45s	4m5s	5m

New colour modification/assignation	1m	56s	50s	43s	35s	31s	23s

Filling of colour-holes	10m	9m6s	8m10s	7m15s	6m25s	5m30s	4m

Merging of colour with the whole coloured model	3m	2m40s	2m20s	2m	1m49s	1m36s	1m10s

Stages	R1	R2	R3

Pre-processing of each view (normal calculation, format conversion, etc.)	5 m	4m30s	4m

Definition of the ortho-image from the 3D model	2m	1m47s	1m35s

Definition of corresponding pairs between the model and the external image	3m	3m10s	3m20s

New colour modification/assignation	1m	56s	50s

Filling of colour-holes	10m	9m6s	8m10s

Merging of colour with the whole coloured model	3m	2m40s	2m20s


Allocation concealment methods	Number of trials (%)

Unclear/not reported	282 (71.76)

Central concealment	21 (5.34)

Sequentially numbered, opaque and sealed envelopes	24 (6.11)

Unsafe envelopes	15 (3.82)

Non-safe methods of allocation	51 (12.98)

Total	393 (100)

Allocation concealment methods	Number of trials (%)

Sequentially numbered, opaque and sealed envelopes	24 (6.11)

Unsafe envelopes	15 (3.82)

Non-safe methods of allocation	51 (12.98)

Total	393 (100)


Group division (n)	Mean alpha angle ± SD

Semiprofessional group (14)	55.16 ± 6.58°

Amateur group (14)	51.65 ± 4.43°

P value	0.11


Characteristics/Outcome	Group I	Group II	Group I and II

	600/750 mg ≥30 kg	300/375 mg 15 – 30 kg	All Participants

Number enrolled	208	238	446

Number completed	203	228	431

Withdrawal/loss to follow up	5(2.5%)	10(4.45)	15(3.5%)

Adequate Clinical and Parasitological Response (ACPR)

 Day 28*	202(99.5%)	222(97.4%)	424(97.45%)

Parasite Clearance Time	40.1 hrs	42.4 hrs	41.3


HAS2	ZEISS Objective

Parameter	Value	Parameter	Value

Overall dimensions 	30 mm × 30 mm 	f	85 mm

Image sensor format	1024 × 1024 pixels	F/#	1.4

Pixel size 	18 μm	Diameter	60.7 mm

ADC resolution 	12 bit 	Image diameter	43 mm

Saturation voltage output 	1.49 V 	FOV	12.42 deg

Full well capacity 	105 e	Pixel scale	44.15 arcsec/pix

Quantum Efficiency 	45% (500–650 nm)

Spectral response 	33.3% (400–900 nm )

Conversion factor 	14.8 μV/e

Dark current 	12.5 e/pix/s

RON 	2 e/pix


	Early-onset Disease (n = 22)	Late-onset Disease (n = 46)	Totala(n = 68)

V	1 (4.5%)	2 (4.3%)	3 (4.4%)


Session	Depression-specific topics	Diabetes-specific topics added

1	Psychoeducation	Connection diabetes and depression

2	Behavioural activation	Worrying about diabetes-related complications

3	Problem solving I	Diabetes and relationship/sexuality

4	Problem solving II	Rumination about diabetes

5	Behavioural activation, focus on physical activity and self-esteem	Physical activity and diabetes

6	Plan for the future	Conversation with a general practitioner

Additional components

Session	Depression-specific topics	Diabetes-specific topics added

7	Overweight/obesity	Diabetes and nutrition

8	Insomnia	---

Session	Depression-specific topics	Diabetes-specific topics added

Booster	Summary: Behavioural activation; Problem solving	Choice of the known topics (1-6)

Session

1

2

3

4

5

6

Additional components

Session

7

8

Session

Booster

Depression-specific topics	Diabetes-specific topics added

Psychoeducation	Connection diabetes and depression

Behavioural activation	Worrying about diabetes-related complications

Problem solving I	Diabetes and relationship/sexuality

Problem solving II	Rumination about diabetes

Behavioural activation, focus on physical activity and self-esteem	Physical activity and diabetes

Plan for the future	Conversation with a general practitioner

Additional components

Depression-specific topics	Diabetes-specific topics added

Overweight/obesity	Diabetes and nutrition

Insomnia	---

Depression-specific topics	Diabetes-specific topics added

Summary: Behavioural activation; Problem solving	Choice of the known topics (1-6)


	Applied in specialty	Auditioned in specialty	% matched at audition (n)

Radiation oncology	5	5	80 (4)

PM&R	6	5	60 (3)

Orthopedics	33	31	58 (18)

Plastic surgery	7	7	57 (4)

Pediatrics	120	65	49 (32)

Psychiatry	35	16	44 (7)

Anesthesia	47	17	41 (7)

Med/peds	12	5	40 (2)

Internal medicine	150	69	39 (27)

Neurosurgery	6	6	33 (2)

Urology	11	11	36 (4)

Emergency medicine	59	56	32 (18)

Ophthalmology	19	17	35 (6)

Otolaryngology	14	12	33 (4)

Neurology	15	10	30 (3)

Family medicine	50	24	29 (7)

Radiology	46	28	28 (8)

OB/GYN	41	30	23 (7)

Dermatology	20	18	17 (3)

General surgery	44	33	3 (1)

Pathology	9	5	0

Prelim medicine only	3	0	0


Total CAS Score	Rating of Intervention Effectiveness	Total No. Studies with each CAS Score

	0	0.5	1

0	1	0	0	1

1	1	1	0	2

2	1	3	0	4

3	0	7	11	18

4	0	1	6	7

Total No. Studies at each Level of Effectiveness	3	12	17	32

Total CAS Score	Rating of Intervention Effectiveness

	0	0.5	1

0	1	0	0

1	1	1	0

2	1	3	0

3	0	7	11

4	0	1	6

Total No. Studies at each Level of Effectiveness	3	12	17

Total No. Studies with each CAS Score

1

2

4

18

7

32


Characteristics	Number of patients	%

Total analyzed	149

Sex

 Males	59	40

 Females	90	60

Median Age (years)	48

 Range	16–85

AJCC stage

 IA	50	33

 IB	22	15

 IIA	36	24

 IIB	12	8

 IIC	1	1

 III	28	19

Primary site

 Head and Neck	13	9

 Superior limbs	23	15

 Inferior limbs	47	32

 Trunk	63	42

 Unknown	3	2


Laboratory tests	result	Normal range

K	5.2	3.4–5.3 mmol /L

Na	137	137–147 mmol /L

Cl	102	99–108 mmol /L

Ca	9.5	8.7–10.7 mg /dL

Lactate	4	0.9–1.8 mmol /L

Ammonia	150	25-80 mmol /L

FBS	85	60–99 mg /dL

BUN	7	5–18 mg /dL

Cr	0.7	0.75–1.20 mg /dL

Laboratory tests	result	Normal range

Ammonia	150	25-80 mmol /L

FBS	85	60–99 mg /dL

BUN	7	5–18 mg /dL

Cr	0.7	0.75–1.20 mg /dL


Characteristics	Females (number)	Age (years)	Duration of symptoms (months)	Symptoms preceeding malignancy (number)	Malignancy

All tumors (number)	Lung cancer (number)

All patients	11/18	61 (48–76)	4 (1–36)	15/18	16/18	14/18

Peripheral neuropathy	5/8	59 (54–76)	3 (1–36)	7/8	7/8	5/8

Encephalitis	6/10	61 (48–74)	4 (1–15)	8/10	9/10	9/10

Rhombencephalitis	3/7	61 (48–73)	13 (3–15)	6/7	6/7	6/7

Limbic encephalitis	3/3	55, 61, 74	1, 3, 4	2/3	3/3	3/3

p value	1.0	0.6	0.5	1.0	1.0	0.3

Characteristics	Females (number)	Age (years)	Duration of symptoms (months)	Symptoms preceeding malignancy (number)	Malignancy

All tumors (number)	Lung cancer (number)

All patients	11/18	61 (48–76)	4 (1–36)	15/18	16/18	14/18

Peripheral neuropa	5	59	3	7	7/	5


Attribute	Value	% of Total

Genome size (bp)	3,086,721	100.00

DNA coding (bp)	2,284,152	74.00

DNA G+C (bp)	2,147,191	69.56

DNA scaffolds	109

Total genes	2,422	100.00

Protein coding genes	2,363	97.56

RNA genes	50	2.06

Pseudo genes	9	0.37

Genes in internal clusters	811	34.32

Genes with function prediction	1633	67.42

Genes assigned to COGs	1858	76.71

Genes with Pfam domains	2038	84.14

Genes with signal peptides	539	22.81

Genes with transmembrane helices	527	22.25

CRISPR repeats	1	0.41

Attribute	Value

Genome size (bp)	3,086,721

DNA coding (bp)	2,284,152

DNA G+C (bp)	2,147,191

DNA scaffolds	109

Total genes	2,422

Protein coding genes	2,363

RNA genes	50

Pseudo genes	9

Genes in internal clusters	811

Genes with function prediction	1633

Genes assigned to COGs	1858

Genes with Pfam domains	2038

Genes with signal peptides	539

Genes with transmembrane helices	527

CRISPR repeats	1


 	PE patients	DVT patients

 	(n=305)	(n=138)

Fatal pulmonary embolism	76 (24.9%)	6 (4.3%)

Respiratory insufficiency	55 (18.0%)	22 (15.9%)

Neoplasia	44 (14.4%)	37 (26.8%)

Infection	32 (10.5%)	14 (10.1%)

Fatal bleeding	17 (5.6%)	8 (5.8%)

Heart failure	10 (3.3%)	6 (4.4%)

Sudden death	6 (2.0%)	6 (4.4%)

Multi-organ failure	6 (2.0%)	5 (3.6%)

Myocardial infarction	5 (1.6%)	2 (1.5%)

Bowel occlusion	3 (1.0%)	1 (0.7%)

Liver insufficiency	2 (0.7%)	1 (0.7%)

Stroke	1 (0.3%)	2 (1.4%)

Terminal renal insufficiency	1 (0.3%)	2 (1.4%)

Critical limb ischemia	1 (0.3%)	0

Other	11 (3.6%)	2 (1.5%)0

Unknown	35 (11.5%)	24 (17.4%)


Characteristics	n	%

Age (y)

≤35	110	10.7

36–50	527	51.1

>50	395	38.3

cT stage

T1	575	55.7

T2	398	38.5

Tx	59	5.7

pT stage

T1	658	63.8

T2	271	26.2

Tx	103	10.0

pN stage

N0	736	71.3

N1	209	20.3

N2	50	4.8

N3	30	3.9

Unknown	7	0.7

Grade

G1	83	8.1

G2	590	57.4

G3	354	34.5

Menopausal status

Pre-	652	63.2

Post-	379	36.8

Margin status

Negative	823	79.7

Carcinoma in situ	87	8.4

Invasive carcinoma	122	11.8

Presence of LVI	114	11.9

Presence of EIC	102	9.9

ER or PR positive	826	80.0

HER-2 positive	216	12.0

Histological subtype

Invasive ductal carcinoma	805	78.0

Presence of DCIS component	83	8.0

Invasive lobular carcinoma	29	2.8

Other	115	11.2

Breast cancer subtype

Luminal A	540	52.3

Luminal B	154	14.9

Luminal-HER-2	132	12.8

HER-2 positive	84	8.1

TN	122	11.8

Characteristics	n	%

>50	395	38.3

cT stage

T1	575	55.7

T2	398	38.5

Tx	59	5.7

pT stage

T1	658	63.8

T2	271	26.2

Tx	103	10.0

pN stage

N0	736	71.3

N1	209	20.3

N2	50	4.8

N3	30	3.9

Unknown	7	0.7

Grade

G1	83	8.1

G2	590	57.4

G3	354	34.5

Menopausal status

Pre-	652	63.2

Post-	379	36.8

Margin status

Negative	823	79.7

Carcinoma in situ	87	8.4

Invasive carcinoma	122	11.8

Presence of LVI	114	11.9

Presence of EIC	102	9.9

ER or PR positive	826	80.0

HER-2 positive	216	12.0

Histological subtype

Invasive ductal carcinoma	805	78.0

Presence of DCIS component	83	8.0

Invasive lobular carcinoma	29	2.8

Other	115	11.2

Breast cancer subtype

Luminal A	540	52.3

Luminal B	154	14.9

Luminal-HER-2	132	12.8

HER-2 positive	84	8.1

TN	122	11.8


	Perceived general health ('excellent/very good/good' = 1)

	Model 1a	Model 1b	Model 2

% of green (1 km)	.010 (.003) [p = .002]	.011 (.003) [p = .005]

% of green (3 km)			.006 (.005) [p = .194]

Time spent on cycling for commuting purposes (minutes)		-.001 (.001) [p = .095]


	Rice			Arabidopsis

Groups	Tissues	Genes	Groups	Tissues	Genes

Preferential expression in young vegetative tissues

IA	Youngest seedling (w/o root)	CESA5,6; CSLC1,7; CSLD4	IIIC	Youngest seedling (w/o root)	CESA5; CSLC4; CSLA3,7

IB	Young seedling (w/root)	CESA1,3,8; CSLF6,8; CSLC2; BC1L14	IIID	Young seedling (w/root)	CESA1,3,6,2; COB

Preferential expression in reproductive stages

/	/	/	IA	Seed, silique	CESA9,10; COBL2,6

IIA(a)	Hull	CSLF2, 7		Silique	CSLC5

IIA(b)	Stem, hull	CESA4,7,9; BC1	IB	Stem, silique	CESA4,7,8;COBL4

/	/	/	IC	Flowers(sepals)	CSLG2,3; CSLB2

/	/	/		Flowers(Carpels)	CSLG1

IIB	Flag leaf and sheath	CSLE1; CSLH3; CESA11	/	/	/

IIC	Flag leaf and endosperm	CSLA3,6,11; BC1L9	/	/	/

Preferential expression in tissues undergoing rapid extension

/	/	/	IIA	Shoot apex, Cauline leaf, Carpel	CSLD5; CSLC8; CSLA15; COBL1,7

/	/	/	IIB	Flowers (Carpels)	CSLD6; CSLA1,2,10,11

IIIB	Stamen and endosperm	CSLC9,CSLD3,5; CSLH2; BC1L5	IIC	Stamen (Pollen)	CSLA9; CSLC6,12; CSLD1,4; COBL10,11

IIID	Radicle and root	CSLD1,2; CSLC3; CSLF3; BC1L1	IIIA, IIIB	Roots	CSLD2,3; CSLA14; CSLB3,4;COBL5,8,9; CSLE1

IIIA	Callus and young panicle	CSLA2,4,7; CSLE2; CSLH1	/	/	/

IIIC	Young panicle	CESA2,9; CSLC10; BC1L2	/	/	/

IIIE	Seed imbibition	CESA1; CSLF9	-	-	-

	Rice			Arabidopsis

Groups	Tissues	Genes	Groups	Tissues	Genes

Preferential expression in young vegetative tissues

IA	Youngest seedling (w/o root)	CESA5,6; CSLC1,7; CSLD4	IIIC	Youngest seedling (w/o root)	CESA5; CSLC4; CSLA3,7

IB	Young seedling (w/root)	CESA1,3,8; CSLF6,8; CSLC2; BC1L14	IIID	Young seedling (w/root)	CESA1,3,6,2; COB

Preferential expression in reproductive stages

/	/	/	IA	Seed, silique	CESA9,10; COBL2,6

IIA(	Hul	CSLF		Sil	CSL

a)	l	2, 7		ique	C5

IIA(b)	Stem, hull	CESA4,7,9; BC1	IB	Stem, silique	CESA4,7,8;COBL4

/	/	/	IC	Flowers(sepals)	CSLG2,3; CSLB2

/	/	/		Flowers(Carpels)	CSLG1

IIB	Flag leaf and sheath	CSLE1; CSLH3; CESA11	/	/	/

IIC	Flag leaf and endosperm	CSLA3,6,11; BC1L9	/	/	/

Preferential expression in tissues undergoing rapid extension

/	/	/	IIA	Shoot apex, Cauline leaf, Carpel	CSLD5; CSLC8; CSLA15; COBL1,7

/	/	/	IIB	Flowers (Carpels)	CSLD6; CSLA1,2,10,11

IIIB	Stamen and endosperm	CSLC9,CSLD3,5; CSLH2; BC1L5	IIC	Stamen (Pollen)	CSLA9; CSLC6,12; CSLD1,4; COBL10,11

IIID	Radicle and root	CSLD1,2; CSLC3; CSLF3; BC1L1	IIIA, IIIB	Roots	CSLD2,3; CSLA14; CSLB3,4;COBL5,8,9; CSLE1

IIIA	Callus and young panicle	CSLA2,4,7; CSLE2; CSLH1	/	/	/

IIIC	Young panicle	CESA2,9; CSLC10; BC1L2	/	/	/

IIIE	Seed imbibition	CESA1; CSLF9	-	-	-


Classification Algorithm	Acronym

Fisher Discriminant Analysis	FDA

Fuzzy Min-Max Neural Network	FMMNN

Kernel Linear Discriminant Analysis	GK-FDA

Kernel Support Vector Machine	GK-SVM

Fuzzy C-Means 	FCM


	PlateliaTM Dengue NS1 Ag-ELISA	Sensitivity(95% CI)	p-value

Overall sensitivity	Non-dissociated	47.8(39.3 – 56.4)	p < 0.001

Heat dissociated	57.7(49.5 – 65.5)

Type of infection	Primary	Non-dissociated	80.9(58.1 – 94.6)	p < 0.001

Heat dissociated	84.6(65.1 – 95.6)

Secondary	Non-dissociated	42.0(33.0 – 51.4)	p < 0.001

Heat dissociated	52.3(43.3 – 61.1)


Assemblathon metrics	RJ	SGA	Edena	LEAP

Ambiguous Contigs	2631	3876	2619	799

- total length	369284	483895	366418	93102


Population	Sample size	Sampling location	Longitude and latitude

	90	Minqing County, Fujian Province,	118.3, 25.6

Han	95	Chengdu City, Sichuan Province,	104.1, 30.6

	30	Yining, Xinjiang Autonomous Region	80.5, 43.3

Oroqen	66	Arlihe, Inner Mongolia Autonomous Region	131.0, 53.5

Ewenk	45	Molidawa, Inner Mongolia Autonomous Region	118.6, 48.0

Korean	157	Yanji City, Jilin Province	121.4, 40.2

Daur	37	Molidawa, Inner Mongolia Autonomous Region	118.6, 40.8

Hezhen	95	Tongjiang, Heilongjiang Province	132.5, 46.7

Man	103	Xiuyan City, Liaoning Province	123.2, 40.2

Kyrgyz	42	Wuqia, Xinjiang Autonomous Region	73.4, 39.2

Uygur	57	Yining City, Xinjiang Autonomous Region	80.5, 43.3

Mongol	99	Hailar City, Inner Mongolia Autonomous Region	126.0, 51.0

Hui	118	Tongxin County, Ningxia Autonomous Region	105.9, 36.9

Xibo	74	Yili, Xinjiang Autonomous Region	80.5, 43.3

Hazakh	91	Yining City, Xinjiang Autonomous Region	80.5, 43.3

Bouyei	115	Guizhou City, Yunnan Province	105.7, 26.0


Stage (%)	Correlation withPD-L1 positive	Prognosis ofPD-L1 positive

I/II/III/IV

0/0/0/100	-	-

0/0/0/100	-	-

0/0/0/100	KRAS mutation	-

50/50(II+III)/0	Younger: High tumor grade	Better

41.7/25.2/28.1/5.0	NS	Poor

-/-/-/88	NS	NS

25.4(I-III)/74.6	Smoking	-

29.4/25.3/45.3/0	Histology; TILs; tumor stage	NS


Genotype	Actual Values

T102C

TT	108

TC	194

CC	48

A-1438G

AA	73

AG	181

GG	96


Risk factors	Univariate	Multivariate

P-value	RR	95%CI	P-value

Age, ≤60 vs. >60 years	0.006*			0.763

Gender, male vs. female	0.24

Site, Head and neck vs. Body and tail	0.15

Tumor size, ≤3.5 vs. >3.5cm	0.55

Tumor differentiation, well/moderate vs. poor	0.000*	1.896	1.077-3.337	0.027*

Stage (AJCC), I-II vs. III-IV	0.001*	3.614	1.228-10.64	0.020*

T stage, pT1-T2 vs. pT3-T4	0.27

Lymph nodes, negative vs. positive	0.012*			0.26

Metastasis, negative vs. positive	0.010*	1.397	0.775-2.520	0.012*

CD133, negative vs. positive	0.000*	2.208	1.161-4.203	0.016*

BMI-1, negative vs. positive	0.000*	2.661	1.256-5.638	0.011*

Co-expression of CD133 and BMI-1, others vs. CD133+/BMI-1+	0.000*	3.523	1.365-9.089	0.009*


Subtheme	Quote

Previous experiences with teletraining	“What I actually find more useful [in Rural Grand Rounds] is quite often he gets paediatricians, emergency medicine from [bigger regional centres], from everywhere who actually do speeches and talks” [PF 4]

“So yeah, that lack of physical-ness about the situation means often you can get apathetic and sometimes just be a bit blasé about it all and sign on just because you have to sign on” [PF 3]

“Oh, I think it serves a purpose. So these people are spread off all over North Queensland and the distances that are involved are prohibitive for everyone together on a really regular basis” [PF 3]

Face to Face versus videoconference learning	“I think any access to any teaching would be appropriate and even if you do not pick up at come place like do not pick up as much from face to face teaching...Sometimes telehealth teaching can teach you maybe if you do pick up 50% of it just because it's ongoing” [PF 5]

“I think tele-training is the way of the future especially for people in our area that more and more of us are going out to rural sites” [RR 2]

Peer teaching	“The best benefit is you get to experience different thinking outside the box and different ways of doing things that apply to rural areas, rather than the textbook stuff that does not always apply” [PF 6]

“I enjoy catching up with people that are in a similar role and have a chance to debrief and have a chance to learn from each other and that is not really a lot of opportunity for that, and the peer education, just people in the same situation and learning from things they have seen and done before, that is probably the only thing I have noticed as a difference” [PF 1]

Teaching skills using videoconference	“I think though that there are certain skills that you need to do person - face-to-face and have immediate feedback on” [RG 2]

“Unfortunately the technology is what people take away from those learning opportunities; they do not take away the actual message of simulation” [RG 6]

“There is no reason why they cannot create a resus with a mannequin, put a dress on it and bring it to the ED and run their own simulation. We all have inherent skills and knowledge. Doing simple stuff, it does not need to be complex” [RG 6]

“The biggest issue with rural is that often you plan to do something every week ...then it just falls off the radar... I think you'd need to have a bunch of passionate people at a centralised location to really push it to happen every week” [PF 4]

“I do not see why you would need someone to teach a practical skill online as a teleconference when you can use YouTube, pause it and revisit all of the steps” [PF 6]

Didactic versus interactive sessions	“Interactive, I definitely prefer, but sometimes in the early years of GP training, a lot of the stuff was a bit didactic, but I did not mind that, I found it to be quiet useful” [GPRNH]

“There would be scope for that as long as it's not didactic lectures, as long as there can be interaction and the facilitators have a skill in that and the people who are being educated, the students, are prepared enough to interact...it would have to be an interactive thing otherwise you can get that from a YouTube, cannot you?” [RG 3]

Subtheme	Quote

Teaching skills using videoconference	“The biggest issue with rural is that often you plan to do something every week ...then it just falls off the radar... I think you'd need to have a bunch of passionate people at a centralised location to really push it to happen every week” [PF 4]

“I do not see why you would need someone to teach a practical skill online as a teleconference when you can use YouTube, pause it and revisit all of the steps” [PF 6]

Didactic versus interactive sessions	“Interactive, I definitely prefer, but sometimes in the early years of GP training, a lot of the stuff was a bit didactic, but I did not mind that, I found it to be quiet useful” [GPRNH]

“There would be scope for that as long as it's not didactic lectures, as long as there can be interaction and the facilitators have a skill in that and the people who are being educated, the students, are prepared enough to interact...it would have to be an interactive thing otherwise you can get that from a YouTube, cannot you?” [RG 3]


Characteristic	N	%

Age (Years)

 <40	39	5.6

 40-49	165	23.7

 50-59	215	30.9

 60-69	214	30.8

 70+	62	8.9

BMI (kg/m2)

 <21	98	14.1

 21-24.9	228	32.8

 25-29.9	218	31.4

 30+	151	21.8

Biopsy technique

 Stereotactic	381	54.8

 Ultrasound-guided	194	27.9

 MRI-guided	120	17.3

Referral group

 Screening	83	11.9

 History of breast cancer	90	13.0

 Clinical symptoms	128	18.4

 Only images	394	56.7

BIRADS

 2-3	75	10.8

 4	346	49.8

 5	204	29.3

 6	70	10.1

Radiological findings

 Radiological focus	396	57.0

 Microcalcification	346	49.8

Mammographic breast density (ACR)

 almost entirely fatty	58	8.4

 fibroglandular	282	41.0

 heterogenous dense	283	41.1

 extremely dense	65	9.5

Mammographic breast density (Computer-based assessment)

 <10%	242	34.8

 10% to <25%	181	26.0

 25% to <50%	186	26.8

 ≥50%	86	12.4

Characteristic

Age (Years)

<40

40-49

50-59

60-69

70+

BMI (kg/m2)

<21

21-24.9

25-29.9

30+

Biopsy technique

Stereotactic

Ultrasound-guided

MRI-guided

Referral group

Screening

History of breast cancer

Clinical symptoms

Only images

BIRADS

2-3

4

5

6

Radiological findings

Radiological focus

Microcalcification

Mammographic breast density (ACR)

almost entirely fatty

fibroglandular

heterogenous dense

extremely dense

Mammographic breast density (Computer-based assessment)

<10%

10% to <25%

25% to <50%

≥50%


 	Adult learning disability	Head and neck cancer	Other

Non aspiration pneumonia	Aspiration pneumonia	Non aspiration pneumonia	Aspiration pneumonia	Non aspiration pneumonia	Aspiration pneumonia

Number of subjects (M/F)	8/8	3/6	23/16	1/3	269/211	96/43

Age in years (mean ± sd)	52 ± 17	56 ± 11	59 ± 13	70 ± 17	73 ± 16	80 ± 13


Clinical/Laboratory/ Radiological Finding	Specification

Impaired consciousness or unrousable coma	Glasgow Coma Scale ≤10b

Multiple convulsions	>2 episodes within 24 h or generalized seizures

Respiratory distress or acidotic breathing	Requirement of noninvasive or endotracheal mechanical ventilationb or respiratory rate of ≥40 breaths/min on room air

Circulatory collapse or shock	Systolic blood pressure <80 mm Hg or ≤80 mm Hg despite volume repletion

Acute pulmonary edema	Verified radiologically

Acute respiratory distress syndrome	Verified radiologically

Acute kidney injury/renal impairment	Serum creatinine >265 μmol/L

Acidosis or hyperlactatemia	pH <7.25 or plasma bicarbonate <15 mmol/L or lactate >5 mmol/L

Clinical jaundice plus evidence of other vital organ dysfunction	Bilirubin >50 μmol/L together with circulatory instability, respiratory distress, impaired consciousness, severe coagulopathy, or acute kidney injury

Severe normocytic anemia	Hemoglobin <70 g/L not related to other cause than the malaria infection

Abnormal bleeding	Spontaneous bleeding from gums, mouth, or gastrointestinal tract

Macroscopic hemoglobinuria	Unequivocally related to acute malaria and verified by urine dipstick

Hypoglycemia	Blood glucose <2.2 mmol/L

Hyperparasitemia	Parasitemia >5%

Clinical/Laboratory/ Radiological Finding

Impaired consciousness or unrousable coma

Multiple convulsions

Respiratory distress or acidotic breathing

Circulatory collapse or shock

Acute pulmonary edema

Acute respiratory distress syndrome

Acute kidney injury/renal impairment

Acidosis or hyperlactatemia

Clinical jaundice plus evidence of other vital organ dysfunction

Severe normocytic anemia

Abnormal bleeding

Macroscopic hemoglobinuria

Hypoglycemia

Hyperparasitemia

Specification

Glasgow Coma Scale ≤10b

>2 episodes within 24 h or generalized seizures

Requirement of noninvasive or endotracheal mechanical ventilationb or respiratory rate of ≥40 breaths/min on room air

Systolic blood pressure <80 mm Hg or ≤80 mm Hg despite volume repletion

Verified radiologically

Verified radiologically

Serum creatinine >265 μmol/L

pH <7.25 or plasma bicarbonate <15 mmol/L or lactate >5 mmol/L

Bilirubin >50 μmol/L together with circulatory instability, respiratory distress, impaired consciousness, severe coagulopathy, or acute kidney injury

Hemoglobin <70 g/L not related to other cause than the malaria infection

Spontaneous bleeding from gums, mouth, or gastrointestinal tract

Unequivocally related to acute malaria and verified by urine dipstick

Blood glucose <2.2 mmol/L

Parasitemia >5%


	Lab studies	Outdoor studies

1980-1985	Collection & screening of algae	Wastewater treatment, small pond studies

1985-1990	Classification of algae biochemistry & physiology of lipid production	Large pond studies

1990-1996	Genetic engineering	Systems analysis & resource assessment

	Lab studies	Outdoor studies

1980-19	Collection & screening of 	Wastewater tr

85	algae	eatment, small pond studies

1985-1990	Classification of algae biochemistry & physiology of lipid production	Large pond studies

1990-1996	Genetic engineering	Systems analysis & resource assessment


Number	Vitamin E succinate (%)	Vitamin E acetate (%)	Gamma- tocopheryl succinate(%)

12	119.3 ± 4.3	0	0.57

13	0	9.3	0

14	0	84.7	0


	Trimmed population	Stratified-matched population

	Rituximab (n = 265)	Anti-TNF (n = 737)	Standardized difference	Rituximab(n = 205)	Anti-TNF(n = 205)	Standardized difference

Prednisone, %	43.8	29.3	0.303	39.0	38.5	0.010

Methotrexate, %	57.7	55.9	0.037	57.1	51.7	0.108

Non-methotrexate nbDMARD, %	29.1	24.8	0.095	29.8	30.2	0.011


Gene Family Member	Enriched Genes	Cases	Controls	Gene Network Association

	No.	Frequency	No.	Frequency	#	Frequency	Pfisher	Enrichment	Pperm

AKAP13	7/7	1.00	16	0.0035	1	0.0002	1.14E−04	16.43	0.012


LA responses (mmol.L−1)	Pre-RF	Beg-RF	End-RF	After-RF	F	p

Resting LA	1.27±0.33	1.11±0.28	1.18±0.30	1.12±0.37	1.45	0.240


Primer name	Direction	Nucleotide sequence (5' to 3')

KSC138-9	Forward	GCACAATAAATTGGGCCTGA

	Reverse	GCGAGTGTTGGGCTAAGTCT

KSC138-10	Forward	CACGAATGTGAATTTGATCG

	Reverse	CGACCAAGGAGATAAAAACAGA

KSC138-17	Forward	TGGAAATTCTGTGCACTTGGTG

	Reverse	TAAAGCCGCCTAGCCGATTG

KSC138-22	Forward	TGCAGCAATAATCAATCAAATAGAA

	Reverse	TTCAATCAAATTTAGCACGTGTATT

KSC138-23	Forward	CGGTCCAGATTTAATTCTTTCACTC

	Reverse	TTTCCGTTTTGTCACCCTGCT

BARCSOYSSR_09_1388	Forward	TTGCACTCTCCAAACCAAGA

	Reverse	ATGCACTCTGCTCGACACAT

BARCSOYSSR_09_1415	Forward	CACCATCCACTCCAGTTCCT

	Reverse	CTCCACGTGTTAGACGGGTT

Primer name	Direction	Nucleotide sequence (5' to 3')

KSC138-22	Forward	TGCAGCAATAATCAATCAAATAGAA

	Reverse	TTCAATCAAATTTAGCACGTGTATT

KSC138-23	Forward	CGGTCCAGATTTAATTCTTTCACTC

	Reverse	TTTCCGTTTTGTCACCCTGCT

BARCSOYSSR_09_1388	Forward	TTGCACTCTCCAAACCAAGA

	Reverse	ATGCACTCTGCTCGACACAT

BARCSOYSSR_09_1415	Forward	CACCATCCACTCCAGTTCCT

	Reverse	CTCCACGTGTTAGACGGGTT


Decoy	RNA	Length	Method	Enrichment score (RMSD)	Enrichment score (DI)


Databases	PubMed	Embase	CINAHL

(“Saudi Arabia”[MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH]	114 (76), Ex: 38 (date range)	1015 (853) Ex: 162 (DR)	20 (20) Ex: 0 (DR)

(“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH]	77 (34) Ex: 43 (date range)	0	51 (39) Ex: 12 (DR)

((“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH]	0	0	0

Total	1277


Exercise	Dosage

Abduction in sidelying	3 sets of 10 at a 10 RM resistance

 Unilateral hip abduction performed in sidelying with the use of ankle cuff weights

Abduction in standing	3 sets of 10 with moderate resistance band

 Unilateral hip abduction performed in standing with the use of resistance band

Standing wall isometric hip abduction	3 sets of 10 with 5 second holds

 Performed in unipedal stance with the opposite limb in 90 degrees of hip and knee flexion. Exercises will be done for both limbs.

Adduction in sidelying	3 sets of 10 at a 10 RM resistance

 Unilateral hip adduction performed in sidelying with the use of ankle cuff weights if possible

Abduction in standing	3 sets of 10 with moderate resistance band

 Unilateral hip abduction performed in standing with the use of resistance band

Towel squeezes	3 sets of 10 with 5 second holds

 Bilateral isometric hip adduction against a rolled-up towel in sitting

Exercise	Dosage

Unilateral hip adduction performed in sidelying with the use of ankle cuff weights if possible

Abduction in standing	3 sets of 10 with moderate resistance band

Unilateral hip abduction performed in standing with the use of resistance band

Towel squeezes	3 sets of 10 with 5 second holds

Bilateral isometric hip adduction against a rolled-up towel in sitting


Study	Genotype	Sex	N	Key Experimental Outcomes

Epithelial CellProliferation	WT	Both	14	In Fgf15-/- mice, we detected a shift of proliferating cells to upper crypt zones (P <0.001).

M	8

F	6

Fgf15-/-	Both	15

M	8

F	7

No Carcinogen Treatment	WT	Both	12	After >1 year surveillance without carcinogen treatment, no WT or Fgf15-/- mouse developed colon neoplasia.

M	4

F	8

Fgf15-/-	Both	17

M	9

F	8

Colon Tumor Induction (AOM/DSS)	WT	Both	14	Colon tumors were detected in 27 of 29 mice; Fgf15-/- mice had more colon tumors overall (P = 0.003), and in males (P = 0.03) and females (P < 0.05) considered separately.

M	6

F	8

Fgf15-/-	Both	15

M	7

F	8


Item	Person-time	%

Utilization of health services

 Saw a doctor	118	36.4

 Self-medication	108	33.3

 Non use	98	30.3

 Total	324	100.0

Type of selected medical institutions

 Village health clinics or community health service stations	53	44.6

 Township hospital	7	6.2

 District-level hospital	20	16.9

 City-level hospital or above	15	12.3

 Unlicensed private clinic	24	20.0

 Total	118	100.0

Item	Person-time	%

Unlicensed private clinic	24	20.0

Total	118	100.0


Barriers to delivery	Quotes

Time	“Did not have time to complete all activities”. (Teacher, school 20, self-evaluation data)

Environment	“It was weather more than anything you know. The game where we had to have the cones and you had to turn them over, we were out in a force 10 gale and they were just blowing everywhere and they were getting really upset”. (Teacher, school 1, interview data)

Educational understanding	“Some children didn’t have good knowledge of human body - this meant that they needed lots of support with bean bag game”. (Teacher (1), school 41, self-evaluation data)

Behaviour	“I quite often had characters in a bit of a sulk because of it [being put on the ‘smokers’ team]”. (Teacher, school 13, interview data)

Children’s preferences	“Used the same messages but changed the sport to basketball instead of football due to previous issues with some of the girls engaging with the context. The children loved the session”. (Teacher (1), school 8, self-evaluation data)


Variable	Placebo Frequency (%)	Caffeine Frequency (%)

Nervousness	1 (4.8)	5 (23.8)

 AA homozygotes	1 (20)	0 (0)

 C allele carriers	0 (0)	5 (31.3)

Insomnia	3 (14.3)	7 (33.3)

 AA homozygotes	0 (0)	2 (40.0)

 C allele carriers	3 (18.8)	5 (31.3)

Gastrointestinal problems	0 (0)	3 (14.3)

 AA homozygotes	0 (0)	1 (20.0)

 C allele carriers	0 (0)	2 (12.5)

Activeness	3 (14.3)	6 (28.6)

 AA homozygotes	2 (40.0)	1 (20.0)

 C allele carriers	1 (6.3)	5 (31.3)

Irritability	0 (0)	2 (9.5)

 AA homozygotes	0 (0)	0 (0)

 C allele carriers	0 (0)	2 (12.5)

Muscular pain	4 (19)	3 (14.3)

 AA homozygotes	0 (0)	0 (0)

 C allele carriers	4 (25.0)	3 (18.8)

Headache	5 (23.8)	4 (19.0)

 AA homozygotes	1 (20)	1 (20)

 C allele carriers	4 (25.0)	3 (18.8)

Variable	Placebo Frequency (%)	Caffeine Frequency (%)

AA homozygotes	1 (20)	1 (20)

C allele carriers	4 (25.0)	3 (18.8)


S.no.	Lab. no.	Binary code	Octal code	ST	Lineage

1	LN 8	□□□■■■□■■■■■■■■■■■■■■■■■■■■■□□□□■□■■□□□■■■■	73777777413071	Unidentified	Unidentified

2	AC 74	■□□□□□□■■■■■■■■■■■■■□□□■■■■■□■■■□□□□■■■■■■■	403777617560771	Unidentified	Unidentified

3	AC 544	■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■□□□□■■■■■■■	777777777760771	53	T1

4	F 85	□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□■■■■■■■■■	3771	1	BEIJING

5	F99	■■■■■■■■■■■■■■■■■■■■■■■■■□■□□□□■□□□□■■■■■■■	777777775020771	Unidentified	Unidentified


Escalation phase	Extension phase

Dose level(mg/kg)	No. of patients	DLT	Patients with grade 3–4 lirilumab-related adverse events	Dose level(mg/kg)	No. of patients	Patients with grade 3–4 lirilumab-related adverse events

0.015	3	0	0	0.015	9	5

0.3	3	0	0

1	4	0	0

3	4	0	0	3	8	2

6	3	0	1a

10	3	0	0


Protein	Activator	Repressor

AP1	[AP1 SEP]	[AG AG]

AP3	[AP1 SEP], [AG SEP], [AP3 PI]

PI	[AP1 SEP], [AG SEP], [AP3 PI]

AG	[AG SEP], [AG AG]	[AP1 AP1]

SHP	[AG SEP]	[PI AP3]

SEP	[AG SEP], [AP1 SEP], [SEP SEP]


Solvent	Δf	Ex	Emmax	(vA-vF)*(10-3) cm-1	Symbols and labels in Figure 3

EtOH	0.30	275	365	9.0	EtOH

EtOH	0.30	275	365 d	9.0	EtOH

EtOH	0.30	235	373 d	15.7	(EtOH)

DMSO	0.26	280	353	7.4	DMSO

DMSO	0.26	276	351	7.7	DMSO


Blend composition	Electrospinning parameters

Voltage, kV	Solution supply rate, ml/h	Distance between spinneret and collector, cm

3% Tec-80A + 5% GL	19.0	1.3	20

3% Tec-80A + 10% GL	18.5	1.3	20

3% Tec-80A + 15% GL	18.5	1.2	19.5

3% Tec-80A + 20% GL	20.0	1.2	19.5

Blend composition	Electrospinning parameters

Voltage, kV	Solution supply rate, ml/h	Distance between spinneret and collector, cm

5% Tec-80A + 5% GL	19.5	1.3	20

5% Tec-80A + 10% GL	22.5	1.4	20

5% Tec-80A + 15% GL	21.0	1.4	18.5

5% Tec-80A + 20% GL	20.0	1.3	18.5

7% Tec-80A + 5% GL	21.0	1.5	20

7% Tec-80A + 10% GL	22.1	1.3	20

7% Tec-80A + 15% GL	24.0	1.2	19

7% Tec-80A + 20% GL	24.0	1.0	19


Gene	Accession number	Probe sequence (5′-> 3′)

Cd68	NM_001031638	ATCCTCATTTCTTCAGCATGCAATTGACTCAACAGAGTTATCTCCCTTCTCTGTCTTTAAA

RT1-Bb	NM_001004084	CAGCTGTGACAGTTGTGAAATACCCTAGCTTCTGATAACAGAATGAGTTACTTCTTCCCAA

Cd86	NM_020081	TAAGCAAGGATACCCGAAACCTACAAAGATGTATTTTTTGATAACTAATA

Cd80	NM_012926	TGAATCTGAGCTGTACACCATTAGTAGCCAACTAGACTTCAACACGACGTACGACCACTTA

Ccl17	NM_057151	CTGCACAGACCCCAAAGACAAGCATGTGAAGAAGGCCATCAGACACCTGAAAAACCAAAGA

Ccl22	NM_057203	GATATCTGTGCTGACCCCAGGATGCTCTGGGTGAAGAAGATACTCCACAAGTTGGCCTAGA

Ccl22	NM_057203	AAATAAATTTGCTTGCTCCTTTGGAGGGAACAGTGGCCTGGCTTAGCTGAGTGAATGGATA

II12a	NM_053390	ACTTCAGAGCCACAATCATCAGCAGATCACTCTGGACAGAAACATGCTGATGGCTATTGAA

II12b	NM_022611	TTGGTCCACCGAGATTTTAAAAAATTTCAAAAATAAGACTTTCCTGAAGTGTGAAGCACCA

Cd40	NM_134360	ATGGAGGAAAAGCTTTGGCGTCAGGGGTCCGCAGTAATATCTACAGAGTGCAGCAATGCAA

Cd40	NM_134360	ACTGCACAGCTCTTGAGAAGACCCAATGCCAACCGTGCGACTCAGGCGAATTCTCAGCTCA

Ox40L	NM_053552	TTGTGTTACAATACAGTGCGTATGTCTTGAACCTCCAGAAAGTCTGAAGGCTACTAATCCA

Gene	Accession number	Probe sequence (5′-> 3′)

RT1-Bb	NM_001004084	CAGCTGTGACAGTTGTGAAATACCCTAGCTTCTGATAACAGAATGAGTTACTTCTTCCCAA

Cd86	NM_020081	TAAGCAAGGATACCCGAAACCTACAAAGATGTATTTTTTGATAACTAATA

Cd80	NM_012926	TGAATCTGAGCTGTACACCATTAGTAGCCAACTAGACTTCAACACGACGTACGACCACTTA

Ccl17	NM_057151	CTGCACAGACCCCAAAGACAAGCATGTGAAGAAGGCCATCAGACACCTGAAAAACCAAAGA

Ccl22	NM_057203	GATATCTGTGCTGACCCCAGGATGCTCTGGGTGAAGAAGATACTCCACAAGTTGGCCTAGA

Ccl22	NM_057203	AAATAAATTTGCTTGCTCCTTTGGAGGGAACAGTGGCCTGGCTTAGCTGAGTGAATGGATA

II12a	NM_053390	ACTTCAGAGCCACAATCATCAGCAGATCACTCTGGACAGAAACATGCTGATGGCTATTGAA

II12b	NM_022611	TTGGTCCACCGAGATTTTAAAAAATTTCAAAAATAAGACTTTCCTGAAGTGTGAAGCACCA

Cd40	NM_134360	ATGGAGGAAAAGCTTTGGCGTCAGGGGTCCGCAGTAATATCTACAGAGTGCAGCAATGCAA

Cd40	NM_134360	ACTGCACAGCTCTTGAGAAGACCCAATGCCAACCGTGCGACTCAGGCGAATTCTCAGCTCA

Ox40L	NM_053552	TTGTGTTACAATACAGTGCGTATGTCTTGAACCTCCAGAAAGTCTGAAGGCTACTAATCCA


Variables	Number (n)	R-Ras expression	p-value

Positive (n=83)	Negative (n=109)

Gender				0.389

 Male	112	45	67

 Female	80	38	42

Ages (years)				0.528

 >=65	91	42	49

 <65	101	41	60

Tumor location				0.661

 ascending colon	97	41	56

 transverse colon	7	2	5

 descending colon	88	40	48

CEA level (mg/L)		7.20±7.00	17.46±34.66	0.008*

Tumor differentiation				0.886

 Well	21	10	11

 Moderate	135	57	78

 Poor	36	16	20

AJCC stage				0.751

 IIIA	7	4	3

 IIIB	124	53	71

 IIIC	61	26	35

Variables	Number (n)	R-Ras expression	p-value

Positive (n=83)	Negative (n=109)

Moderate	135	57	78

Poor	36	16	20

AJCC stage				0.751

IIIA	7	4	3

IIIB	124	53	71

IIIC	61	26	35


Clinical parameters	Correlation coefficient	P-value (2-tailed)

NSE	−0.168	0.308

SCC	−0.398	0.012a


Initial body wt (g)

Final body wt (g)

Wt gain (g)

Liver wt (g)

Liver wt/body wt (g/100 g)

Food intake (g/mouse/day)

Fecal excretion (g/mouse/day)


Model 2	B	SE	HR	95% CI	p

			Inferior	Superior

Male gend	.		1.97	1	3	0


Threshold on Wells scale = 2	Thrombosis	Without Thrombosis

Number of points on the Wells scale: >2	40	60

Number of points on the Wells scale: ≤2	20	928

Sensitivity: 66.66%	Positive predictive value: 40.00%

Specificity: 93.93%	Negative predictive value: 97.89%

Threshold on Wells scale = 2	Thrombosis

Number of points on the Wells scale: >2	40

Number of points on the Wells scale: ≤2	20

Sensitivity: 66.66%	Positive predictive value: 40.00%

Specificity: 93.93%	Negative predictive value: 97.89%

Without Thrombosis

60

928

Positive predictive value: 40.00%

Negative predictive value: 97.89%


	Probabilities

Variable	No RX	rFVIIa (40 mcg)	rFVIIa (80 mcg)	Utilities	Range

Mild post-ICH deficit (mRS 0–1)	0. 08	0. 17	0. 21	0. 81	0. 70–0. 95

Moderate post-ICH deficit (mRS 2–3)	0. 23	0. 29	0. 29	0. 55	0. 2–0. 65

Severe post-ICH deficit (mRS 4–5)	0. 40	0. 37	0. 30	0. 25	(-0. 2)-0. 45

Death after ICH	0. 29	0. 18	0. 18	0	0

Arterial thromboembolic event		0. 02	0. 02	0. 55

Probability of dying after ATE		0. 29	0. 29

	Probabilities

Mild post-ICH deficit (mRS 0–1)	0. 08	0. 17	0. 21	0. 81	0. 70–0. 95

Moderate post-ICH deficit (mRS 2–3)	0. 23	0. 29	0. 29	0. 55	0. 2–0. 65

Severe post-ICH deficit (mRS 4–5)	0. 40	0. 37	0. 30	0. 25	(-0. 2)-0. 45

Death after ICH	0. 29	0. 18	0. 18	0	0

Arterial thromboembolic event		0. 02	0. 02	0. 55

Probability of dying after ATE		0. 29	0. 29


Country	Existing laws alluding to quality and patient safety

Jordan	In Jordanian law, the Public Health Code includes articles that emphasize the state’s responsibility to provide healthcare, and the Ministry of Health’s responsibility regarding health matters as follows: - Provide illness prevention, curative measures and supervisory services. - Organize and supervise private and public sector health services. - Provide citizens with health insurance within the allotted parameters. - Establish health, educational and training institutions related to the Ministry and to supervise their management once established.

As stipulated in Jordanian Law 9 (1999), the High Health Council is responsible for drafting health policies and developing strategic plans as well as planning health services to ensure equitable access to and provision of outstanding health services to all population. Other institutions include Jordanian Medical Council, Supreme Council for Population, Jordanian Nursing Council, National Council for Family Affairs, General Organization for Food and Drug Administration and Department of Joint Procurement

Lebanon	The Ministerial Decree 7612, issued by the parliament in 2002, which amends the legislative decree 139/83 (1983), states that “the MOPH has the right to evaluate, classify and accredit hospitals according to their status, field of specialty and range of services provided”. The decree 482/1 (2009) sets a national Committee for Accreditation of Hospitals, chaired by the Director General of Health.

Country	Existing laws alluding to quality and patient safety

Jorda	In Jordanian law, the Public Health Code includes articles that emphasize the state’s responsibility to provide healthcare, and the Ministry of Health’s responsibility regarding health matters as follows: - Provide illness prevention, curative measures and supervisory services. - Organize and supervise private and public sector health services. - Provide citizens with health insurance within the allotted parameter

n	s. - Establish health, educational and training institutions related to the Ministry and to supervise their management once established.

As stipulated in Jordanian Law 9 (1999), the High Health Council is responsible for drafting health policies and developing strategic plans as well as planning health services to ensure equitable access to and provision of outstanding health services to all population. Other institutions include Jordanian Medical Council, Supreme Council for Population, Jordanian Nursing Council, National Council for Family Affairs, General Organization for Food and Drug Administration and Department of Joint Procurement

Lebanon	The Ministerial Decree 7612, issued by the parliament in 2002, which amends the legislative decree 139/83 (1983), states that “the MOPH has the right to evaluate, classify and accredit hospitals according to their status, field of specialty and range of services provided”. The decree 482/1 (2009) sets a national Committee for Accreditation of Hospitals, chaired by the Director General of Health.


Type of paper	EpidemiologyN papers (%)N citations	Eur Respir JN papers (%)N citations

National	17 (71)53	10 (53)18

(US)	9 (38)68	1 (5)6

(other)	8 (33)37	9 (48)18

International	7 (29)54	9 (48)23

Inter-European	1 (4)16	6 (32)25


Patients	Professionals

- Do you know anything about lifestyle modification (diet, exercise, etc.) in order to change your mood and depression?- All of you have taken part in a research project about modifying lifestyles. Did these recommendations that were given to you show you something new that you did not know?- Did you follow the recommendations for modifying lifestyles?If NOT, why didn’t you follow them?- How did you feel when you followed the recommendations? And when you didn’t?- What difficulties did you encounter in implementing the recommendations?- Do you think these recommendations helped you?- What do you think about the doctor’s role?- And about the way of carrying out this modification?- Do you think another type of intervention would have helped you? Would an educational group or another kind of intervention have helped you?- Do you think there is something more that can be done to help you to modify your lifestyle when depressed?	- How do you think you should make recommendations for modifying life styles?- And to a patient with depression?- Do you know how this intervention can help him/her?- Do you think these recommendations can be effective? And do you believe the patient thinks that they work?- What difficulties do you think depressed patients have in changing their behaviour?- And what feelings do they have?- And as for modifying lifestyles, do you work in a different way in the case of a depressed patient?- What do you think is necessary in order to be effective when modifying lifestyles?- What do you think about educational groups?- And about follow-up?- Do you think these interventions are feasible from PC?- What difficulties do you encounter when giving this type of advice?- What is the appropriate level (or department or system) to implement this kind of interventions?

Patients

- Do you know anything about lifestyle modification (diet, exercise, etc.) in order to change your mood and depression?- All of you have taken part in a research project about modifying lifestyles. Did these recommendations that were given to you show you something new that you did not know?- Did you follow the recommendations for modifying lifestyles?If NOT, why didn’t you follow them?- How did you feel when you followed the recommendations? And when you didn’t?- What difficulties did you encounter in implementing the recommendations?- Do you think these recommendations helped you?- What do you think about the doctor’s role?- And about the way of carrying out this modification?- Do you think another type of intervention would have helped you? Would an educational group or another kind of intervention have helped you?- Do you think there is something more that can be done to help you to modify your lifestyle when depressed?

Professionals

- How do you think you should make recommendations for modifying life styles?- And to a patient with depression?- Do you know how this intervention can help him/her?- Do you think these recommendations can be effective? And do you believe the patient thinks that they work?- What difficulties do you think depressed patients have in changing their behaviour?- And what feelings do they have?- And as for modifying lifestyles, do you work in a different way in the case of a depressed patient?- What do you think is necessary in order to be effective when modifying lifestyles?- What do you think about educational groups?- And about follow-up?- Do you think these interventions are feasible from PC?- What difficulties do you encounter when giving this type of advice?- What is the appropriate level (or department or system) to implement this kind of interventions?


	Risperidone	Olanzapine	Quetiapine	Ziprasidone	Aripiprazole	FGAs	No medication

S	47 	13 (6/7)	4	2 (		5 (3/2)	39 (22/17


Process	2o rate constant (#min-1)	Enzyme	Enz #	1o rate const (min-1)	PTM modifying rate	Rate MF	Reference

Synthesis (NULL → FOXO)	0.0055	E2F1	300	5.5	 	 	[45] Figure 1

Cytoplasm → nuclear transport	-	-	-	0.1/0.55 = 0.182	 	 	[3], [46]

 	 	 	 	 	Akt-Phos Pa	0.1	[46]

 	 	 	 	 	IKK-Phos Pd	0.5	[47] Figure 1

 	 	 	 	 	JNK-Phos Pe	10	[44]

Nuclear → cytoplasm transport	-	-	-	0.1 × 0.55 = 0.055	 	 	[3], [46]

 	 	 	 	 	Akt-Phos Pa	10	[46]

 	 	 	 	 	IKK-phos Pd	10	[47]

 	 	 	 	 	JNK-Phos Pe	0.1	[44]

Nuclear → DNAbound transport	-	-	-	0.25	 	 	[48]

 	 	 	 	 	Akt-Phos Pa	0.5	[49] Figure 6B

DNAbound → Nuclear transport	-	-	-	0.25 × 0.5 = 0.125	 	 	[48]

basal phosphorylation	5 × 10-5

basal dephosphorylation	1 × 10-6

akt_phos_factor	6

ikk phos_factor	3

jnk phos_factor	2

FOXO → FOXO_Pa	akt phos_factor × basal phosphorylation	Akt	(104)	0.5	 	 	[50] Figure 1C

FOXO_Pa → FOXO	basal dephosphorylation	PP2A	5 × 105	0.5

FOXO → FOXO_Pd	ikk phos_factor × basal phosphorylation	IKK	(104)	0.5	 	 	[47]

FOXO_Pd → FOXO	basal dephosphorylation	PP2A	5 × 105	0.5

FOXO → FOXO_Pe	jnk phos_factor × basal phosphorylation	JNK	(104)	0.5	 	 	[44]

FOXO_Pe → FOXO	basal dephosphorylation	PP2A	5 × 105	0.5

FOXO → FOXO_pUb	1 × 10-6	SCF/MDM2	103	10-3	 	 	[45] Figure 1; also [51]

 	 	 	 	 	Akt (Pa)	3	[45] Figure 1

 	 	 	 	 	IKK (Pd)	22	[47] Figure 5F

Degradation (FOXO_pUb → NULL)	1 × 10-4	Proteasome	103	0.1	 	 	[45] Figure 1

Process	2o rate constant (#min-1)	Enzyme	Enz #	1o rate const (min-1)	PTM modifying rate	Rate MF	Reference

Degradation (FOXO_pUb → NULL)	1 × 10-4	Proteasome	103	0.1			[45] Figure 1


Family	Species	Size of mt DNA (bp)	GenBank accession no.

Babesiidae	B. orientalis	5996	KF218819

 	B. bovis	6005	EU075182

 	B. bovis	5970	AB499088

 	B. bigemina	5924	AB499085

 	B. caballi	5847	AB499086

 	B. gibsoni	5865	AB499087

 	B. rodhaini	6929	AB624357

Theileriidae	T. parva	5895	Z23263

 	T. parve	5924	AB499089

 	T. equi	8246	AB499091

 	T. orientalis	5957	AB499090

 	T. annulata	5905	NT167255

Plasmodiidae	P. falciparum	5967	M76611


	Cause of hospitalization	Cause of death

Event	N	%	N	%

WHO stage 2 events	1	0.65	0	0

WHO 3 non-specific events	10	6.45	0	0

WHO 3 severe events	58	37.42	11	44

WHO stage 4 events	29	18.71	10	40

WHO stage 4 cachexia	9	5.81	0	0

Non-AIDS-defining infection	42	27.10	4	16

Non-AIDS-defining disease	3	1.94	0	0

Secondary effects to treatment	2	1.29	0	0

Uncategorised	1	0.65	0	0

Total	155	100.00	25	100

	Cause of hospitalization	Cause of death

Event	N	%	N	%

WHO stage 4 events	29	18.71	10	40

WHO stage 4 cachexia	9	5.81	0	0

Non-AIDS-defining infection	42	27.10	4	16

Non-AIDS-defining disease	3	1.94	0	0

Secondary effects to treatment	2	1.29	0	0

Uncategorised	1	0.65	0	0

Total	155	100.00	25	100


Microscopy	PCR

	N	Pf	Pv	Pm	Po	Pf/Pv	Pf/Pm	Pv/Po	Negative

Pf	135	117	2	0	0	13	3	0	0

Pv	94	0	82	0	2	9	0	1	0

Pm	1	0	0	1	0	0	0	0	0

Pf/Pv	31	0	0	0	0	30	1	0	0


	Patient N°

	1.	2.	3.	4.	5.

Duration of tube feeding (days)	7	15	8	6	9

Parenteral nutritional support	none	none	12 kcal/kg/day (9 days)	none	none

The start of liquid diet per os	4	7	7	6	6

Cumulative nitrogen balance during first 7 days after surgery	-6 grams	-18 grams	4 grams	0 gram	-8 grams

ICU free days	9	23	12	9	9

Length of hospital stay	10	28	12	9	12

Complications	none	myocardial infarction	urinary infection	none	wound infection

Outcome	discharged	died in 28th post day	discharged	discharged	discharged


Aged parental clone	Origin	Overall haematopoietic chimerism (%±s.d.)	Overall relative chimerism (%±s.d.)	Lineage distribution of test cells in 1°transplants, iPS chimeras and 2° transplants (%±s.d.)	Lineage distribution of young cells (blastocyst/morula-derived; %±s.d.)

 	 	 	 	T cell	B cell	Myeloid	T cell	B cell	Myeloid

M/E clone 1 (myeloid only)	1° Transplant	NA	NA	0	0	100	NA	NA	NA

 	iPS chimera	26.9	100	11.2	60.6	28.2	45.5	32.3	22.2

 	2° Transplant, iPS origin (n=4)	25.8±3.6	113.9±45.4	8.7±4.9	75.4±10.9	15.9±8.9	22.7±9.5	62±6.2	15.3±3.5

M/E clone 2 (myeloid only)	1° Transplant	NA	NA	0	0	100	NA	NA	NA

 	iPS chimera	25.5	100	20.1	60.9	19	58.5	26.1	15.3

 	2° Transplant, iPS origin (n=4)	18.6±3.3	73.1±12.8	10.1±1.7	76.9±6.1	13.1±6.8	26±4.4	61.5±3.6	12.5±4.2

M/E clone 3 (myeloid only)	1° Transplant	NA	NA	0	0	100	NA	NA	NA

 	iPS chimera	55.4	100	32.9	36.8	30.3	55.8	27.2	17

 	2° Transplant, iPS origin (n=4)	60.9±10.4	109.9±18.7	22.3±6	60.9±1.1	16.8±6.4	42.7±5.2	41±7.2	16.3±6.3

M/B/E clone 1 (T-cell deficient)	1° Transplant	NA	NA	0	16.5	83.5	NA	NA	NA

 	iPS chimera	33.7	100	11.5	69.2	19.3	36.9	51.8	11.3

 	2° Transplant, iPS origin (n=5)	27.6±9.7	79.7±32.8	22.4±6.2	64.7±10.1	13±5.9	43.7±6.1	40.7±7.8	15.6±2.3

M/B/E clone 2 (T-cell deficient)	1° Transplant	NA	NA	0	24.5	75.5	NA	NA	NA

 	iPS chimera	22.4	100	29.5	31.7	38.8	62.3	22.3	15.4

 	2° Transplant, iPS origin (n=5)	21.4±4.1	71.9±31.5	12.8±3.7	78.8±3.3	8.3±2.6	29.8±5.3	54.3±1.7	15.9±6.3

Aged parental clone	Origin	Overall haematopoietic chimerism (%±s.d.)	Overall relative chimerism (%±s.d.)	Lineage distribution of test cells in 1°transplants, iPS chimeras and 2° transplants (%±s.d.)	Lineage distribution of young cells (blastocyst/morula-derived; %±s.d.)

M/E clone 2 (myeloid only)	1° Transplant	NA	NA	0	0	100	NA	NA	NA

	iPS chimera	25.5	100	20.1	60.9	19	58.5	26.1	15.3

	2° Transplant, iPS origin (n=4)	18.6±3.3	73.1±12.8	10.1±1.7	76.9±6.1	13.1±6.8	26±4.4	61.5±3.6	12.5±4.2

M/E clone 3 (myeloid only)	1° Transplant	NA	NA	0	0	100	NA	NA	NA

	iPS chimera	55.4	100	32.9	36.8	30.3	55.8	27.2	17

	2° Transplant, iPS origin (n=4)	60.9±10.4	109.9±18.7	22.3±6	60.9±1.1	16.8±6.4	42.7±5.2	41±7.2	16.3±6.3

M/B/E clone 1 (T-cell deficient)	1° Transplant	NA	NA	0	16.5	83.5	NA	NA	NA

	iPS chimera	33.7	100	11.5	69.2	19.3	36.9	51.8	11.3

	2° Transplant, iPS origin (n=5)	27.6±9.7	79.7±32.8	22.4±6.2	64.7±10.1	13±5.9	43.7±6.1	40.7±7.8	15.6±2.3

M/B/E clone 2 (T-cell deficient)	1° Transplant	NA	NA	0	24.5	75.5	NA	NA	NA

	iPS chimera	22.4	100	29.5	31.7	38.8	62.3	22.3	15.4

	2° Transplant, iPS origin (n=5)	21.4±4.1	71.9±31.5	12.8±3.7	78.8±3.3	8.3±2.6	29.8±5.3	54.3±1.7	15.9±6.3


Variable name	ICC (95 % CI)a,b

Maternal information

 Pre-pregnancy weight	0.97 (0.96 –0.97)

 Admission weight	0.94 (0.94 –0.95)

 Height	0.90 (0.89 –0.92)

Antenatal information

 Gravida	0.76 (0.73 –0.78)

 Previous term deliveries	0.99 (0.98 –0.99)

 Previous preterm deliveries	0.86 (0.85 –0.88)

 Previous spontaneous abortions	0.92 (0.91 –0.93)

 Previous therapeutic abortions	0.90 (0.88 –0.91)

 Previous cesarean deliveries	0.99 (0.99 –0.99)

 Previous vaginal deliveries	0.99 (0.99 –0.99)

 Number of living children	0.98 (0.98 –0.99)

 Third trimester hemoglobin	0.85 (0.83 –0.87)

 Gestational age at first ultrasound, in weeks	0.92 (0.90 –0.93)

 Gestational age at first ultrasound, in days	0.90 (0.89 –0.92)

 Total prior admissions this pregnancy	0.59 (0.55 –0.63)

 School years completed	0.92 (0.90 –0.94)

 Number of antenatal visits	0.91 (0.90 –0.92)

Labour and delivery information

 Cervical dilation on admission	0.88 (0.86 –0.90)

 Cervical dilation prior to cesarean delivery	0.96 (0.95 –0.97)

 Postpartum hemoglobin value	0.98 (0.98 –0.98)

Variable name

Maternal information

Pre-pregnancy weight

Admission weight

Height

Antenatal information

Gravida

Previous term deliveries

Previous preterm deliveries

Previous spontaneous abortions

Previous therapeutic abortions

Previous cesarean deliveries

Previous vaginal deliveries

Number of living children

Third trimester hemoglobin

Gestational age at first ultrasound, in weeks

Gestational age at first ultrasound, in days

Total prior admissions this pregnancy

School years completed

Number of antenatal visits

Labour and delivery information

Cervical dilation on admission

Cervical dilation prior to cesarean delivery

Postpartum hemoglobin value


Antimicrobial agent	No. (%) of H. pylori-resistant strains

2006–2008 [13]	2009–2011	P value(1)

n = 115	n = 51


	Crude OR (95% CI)	Adjusted OR (95% CI)

Female gender (vs male)	0.9 (0.5–1.5)

Zhuang ethnicity (vs Han and others)	0.8 (0.5–1.5)

Age group (years): ref. = < 30

 30–39	0.8 (0.4–1.6)

 40–49	0.9 (0.4–1.8)

 ≥ 50	0.7 (0.3–1.5)

Education level: ref. = Illiterate

 Elementary school	4.2 (1.4–12.2)

 Junior high school	3.2 (1.1–9.5)

 High school or higher	4.1 (1.1–15.1)

Marital status: ref. = unmarried

 Married	0.8 (0.5–1.4)

 Divorced or widowed	0.6 (0.2–1.9)

Occupation: ref. = unemployed

 Farmer	1.5 (0.8–2.7)

 Other	1.1 (0.3–3.5)

Annual family income level: ref. = low

 Middle	0.7 (0.4–1.3)

 High	1.0 (0.5–2.1)

Cause of disease

 Other non-organic severe mental disorders (vs organic psychoses)	11.5 (1.6–84.6)	11.6 (1.6–86.0)

Disease duration (years)	1.0 (0.9–1.0)

PANSS score

 Positive scale	1.0 (0.9–1.0)

 Negative scale	1.0 (0.9–1.0)

 General psychopathology	1.0 (0.9–1.0)

Caregiver

 Yes (vs no)	6.2 (2.0–18.3)	3.21 (1.2–8.3)

Caregiver’s gender

 Female (vs male)	1.3 (0.6–2.4)

	Crude OR (95% CI)	Adjusted OR (95% CI)

≥ 50	0.7 (0.3–1.5)

Education level: ref. = Illiterate

Elementary school	4.2 (1.4–12.2)

Junior high school	3.2 (1.1–9.5)

High school or higher	4.1 (1.1–15.1)

Marital status: ref. = unmarried

Married	0.8 (0.5–1.4)

Divorced or widowed	0.6 (0.2–1.9)

Occupation: ref. = unemployed

Farmer	1.5 (0.8–2.7)

Other	1.1 (0.3–3.5)

Annual family income level: ref. = low

Middle	0.7 (0.4–1.3)

High	1.0 (0.5–2.1)

Cause of disease

Other non-organic severe mental disorders (vs organic psychoses)	11.5 (1.6–84.6)	11.6 (1.6–86.0)

Disease duration (years)	1.0 (0.9–1.0)

PANSS score

Positive scale	1.0 (0.9–1.0)

Negative scale	1.0 (0.9–1.0)

General psychopathology	1.0 (0.9–1.0)

Caregiver

Yes (vs no)	6.2 (2.0–18.3)	3.21 (1.2–8.3)

Caregiver’s gender

Female (vs male)	1.3 (0.6–2.4)


R di Pearson p<.05	PF	PRF	BP	GHP	V	SRF	ERF	MH


Evaluation criteria	Description	Temperature and duration	Reference

Treatment	Recovery

Germination stage

Vigor of germination	Vigor of germination (%) = Number of germinated grains/Number of total grains × 100	14°C/7-17 d	-	(Han et al. [2006])

Seedling survival rate	Seedling survival rate (%) = Surviving seedlings/Sprouting seeds × 100, determined when shoots are about 5 mm long.	2°C/3 d	20°C/7 d	(Zhou et al. [2012])

Seedling stage

Fresh weight (FW)	Changes in FW of plants after cold treatment can be used as an indicator of cold damage.	10°C/1-48 h	-	(Bonnecarrère et al. [2011])

Survival rate	Survival rate (%) after cold treatment is calculated as the Number of surviving plants/Total number plants treated × 100	4°C/6 d	26°C/6 d	(Zhang et al. [2011b])

Leaf emergence	New leaf emergence demonstrates maintained vigor and increased growth.	4°C/7 d	25°C/10 d	(Xie et al. [2012])

Seedling growth	1 = dark green seedlings, 3 = light green seedlings, 5 = yellow seedlings, 7 = brown seedlings, 9 = seedlings dead.	9°C/8-14 d	-	(Kim and Tai [2011]; IRRI [2002]; Andaya and Tai [2006])

Leaf growth	A score of 1–3 (tolerant, all leaves normal, no apparent visual injury), or 4–9 (susceptible, all leaves wilted, seedlings apparently dead).	10°C/7 d	25°C/7 d	(Suh et al. [2012])

Metabolic assessments	Metabolites include EL, proline, MDA, and AsA, and GSH.	9°C/1-14 d	-	(Tian et al. [2011]; Zhang et al. [2011a]; Kim and Tai [2011]; Yang et al. [2012])

Enzyme activities	Enzymes include POD, SOD, and CAT, and APX.	4°C/0-4 d	25°C/7 d	(Bonnecarrère et al. [2011]; Huang et al. [2009]; Sato et al. [2001])

Reproductive stage

Spikelet fertility (CGC)	Spikelet fertility is calculated as the ratio of filled grains to the total number of florets, basing on cold greenhouse cultivation.	12°C/6 d	Until maturation	(Sato et al. [2011])

Spikelet fertility (CDWI)	Spikelet fertility is calculated as the same as spikelet fertility (CGC), but the cold treatment is based on cold deep-water irrigation.	18-19°C/~60 d	-	(Shirasawa et al. [2012])

Evaluation criteria

Germination stage

Vigor of germination

Seedling survival rate

Seedling stage

Fresh weight (FW)

Survival rate

Leaf emergence

Seedling growth

Leaf growth

Metabolic assessments

Enzyme activities

Reproductive stage

Spikelet fertility (CGC)

Spikelet fertility (CDWI)

Description	Temperature and duration	Reference

Treatment	Recovery

Vigor of germination (%) = Number of germinated grains/Number of total grains × 100	14°C/7-17 d	-	(Han et al. [2006])

Seedling survival rate (%) = Surviving seedlings/Sprouting seeds × 100, determined when shoots are about 5 mm long.	2°C/3 d	20°C/7 d	(Zhou et al. [2012])

Changes in FW of plants after cold treatment can be used as an indicator of cold damage.	10°C/1-48 h	-	(Bonnecarrère et al. [2011])

Survival rate (%) after cold treatment is calculated as the Number of surviving plants/Total number plants treated × 100	4°C/6 d	26°C/6 d	(Zhang et al. [2011b])

New leaf emergence demonstrates maintained vigor and increased growth.	4°C/7 d	25°C/10 d	(Xie et al. [2012])

1 = dark green seedlings, 3 = light green seedlings, 5 = yellow seedlings, 7 = brown seedlings, 9 = seedlings dead.	9°C/8-14 d	-	(Kim and Tai [2011]; IRRI [2002]; Andaya and Tai [2006])

A score of 1–3 (tolerant, all leaves normal, no apparent visual injury), or 4–9 (susceptible, all leaves wilted, seedlings apparently dead).	10°C/7 d	25°C/7 d	(Suh et al. [2012])

Metabolites include EL, proline, MDA, and AsA, and GSH.	9°C/1-14 d	-	(Tian et al. [2011]; Zhang et al. [2011a]; Kim and Tai [2011]; Yang et al. [2012])

Enzymes include POD, SOD, and CAT, and APX.	4°C/0-4 d	25°C/7 d	(Bonnecarrère et al. [2011]; Huang et al. [2009]; Sato et al. [2001])

Spikelet fertility is calculated as the ratio of filled grains to the total number of florets, basing on cold greenhouse cultivation.	12°C/6 d	Until maturation	(Sato et al. [2011])

Spikelet fertility is calculated as the same as spikelet fertility (CGC), but the cold treatment is based on cold deep-water irrigation.	18-19°C/~60 d	-	(Shirasawa et al. [2012])


Algorithm	Proposed	No Preprocessing	No Verification

Recognition rate	97.8%	98.1%	68.0%

Computation time	1018	4951	736


Case	Response time to deviation	Response time to math

	Mean	Standarddeviation	Difference(dual-single)	Mean	Standarddeviation	Difference(dual-single)

Case 1	0.9480	0.1314	p < 0.01	1.1479	0.3061	p < 0.01

Case 2	0.9856	0.1269	p > 0.01	1.1277	0.2724	p < 0.01

Case 3	0.9865	0.1231	p > 0.01	1.0975	0.2727	p < 0.01

Single (baseline)	1	0.1553		1	0.2168

Case	Response time to deviation	Response time to math

	Mean	Standarddeviation	Difference(dual-single)	Mean

Case 1	0.9480	0.1314	p < 0.01	1.1479

Case 2	0.9856	0.1269	p > 0.01	1.1277

Case 3	0.9865	0.1231	p > 0.01	1.0975

Single (baseline)	1	0.1553		1

Response time to math

Standarddeviation	Difference(dual-single)

0.3061	p < 0.01

0.2724	p < 0.01

0.2727	p < 0.01

0.2168


Year	Tumor type	No. of cases	Culture condition	Authors

1999	Renal cell carcinoma Colorectal carcinoma Lymphoma	10	IFN-γ, anti-CD3, IL2 plus IL-2 transgene	Schmidt-Wolf IG et al. [33]

2005	Lymphoma	9	IFN-γ, anti-CD3, and IL2	Leemhuis T et al. [14]

2006	Gastric carcinoma	57	IFN-γ, anti-CD3, IL2 and IL-1alpha	Jiang JT et al. [34]

2007	Leukemia	11	IFN-γ, anti-CD3 and IL2	Introna M et al. [35]

2008	Non-small cell lung cancer	59	IFN-γ, anti-CD3, IL2 and IL-1alpha	Wu CP et al. [36]

2009	Hepatocellular carcinoma	127	IFN-γ, anti-CD3, IL2 and IL-1lalpha	Hui D et al. [37]

2009	Renal cell carcinoma and lymphoma	6	IFN-γ, anti-CD3, and IL2	Olioso P et al. [38]

2010	Gastric carcinoma	156	IFN-γ, anti-CD3, IL2, and IL-1alpha	Jiang JT et al. [39]

2011	relapsed hematologic malignancies	18	IFN-γ, anti-CD3, and IL2	Laport GG et al. [40]

2012	Renal cell carcinoma	74	IFN-γ, anti-CD3, IL2, IL-1beta	Liu L et al. [41]

Year	Tumor type	No. of cases	Culture condition	Authors

2010	Gastric carcinoma	156	IFN-γ, anti-CD3, IL2, and IL-1alpha	Jiang JT et al. [39]

2011	relapsed hematologic malignancies	18	IFN-γ, anti-CD3, and IL2	Laport GG et al. [40]

2012	Renal cell carcinoma	74	IFN-γ, anti-CD3, IL2, IL-1beta	Liu L et al. [41]


Bacterial name	Inhibitory effects*

Acetic bacteria	-

Bacillus subtilis	+

E. coli	+++

Lactobacillus fermenti	-

Lactobacillus plantarum ZJ316	-

Lactococcus lactis	-

Listeria monocytogenes	++

Micrococcus luteus	+

Pseudomonas aeruginosa	+

Pseudomonas putida	++++

Shigella flexneri	++

Saccharomyces cerevisiae	-

Salmonella	++

Shigella dysenteriae	+

Staphylococcus aureus	+

Staphylococcus citreus	+

Vibrio parahaemolyticus	-

Bacterial name	Inhibitory effects*

E. coli	+++

Lactobacillus fermenti	-

Lactobacillus plantarum ZJ316	-

Lactococcus lactis	-

Listeria monocytogenes	++

Micrococcus luteus	+

Pseudomonas aeruginosa	+

Pseudomonas putida	++++

Shigella flexneri	++

Saccharomyces cerevisiae	-

Salmonella	++

Shigella dysenteriae	+

Staphylococcus aureus	+

Staphylococcus citreus	+

Vibrio parahaemolyticus	-


	Second versus first tertile	Third versus first tertile

Group	β ± SE	p-Value	β ± SE	p-Value

Full (wet weight)

Systolic	0.023 ± 0.09	0.0088	0.028 ± 0.10	0.0092

Diastolic	0.034 ± 0.09	0.0002	0.035 ± 0.10	0.0011

	Second versus first tertile	Third versus first tertile

Group	β ± SE	p-Value	β ± SE	p-Value

Full (lipid adjusted)

Systolic	0.030 ± 0.008	0.01	0.032 ± 0.01	0.006

Diastolic	0.033 ± 0.008	0.0002	0.037 ± 0.10	0.0005

Normotensive (wet weight)

Systolic	0.007 ± 0.006	0.57	0.020 ± 0.007	0.035

Diastolic	0.013 ± 0.007	0.06	0.020 ± 0.008	0.04

Normotensive (lipid adjusted)

Systolic	0.011 ± 0.006	0.075	0.023 ± 0.007	0.002

Diastolic	0.018 ± 0.007	0.012	0.026 ± 0.008	0.003


Insertions of transgenes	Relative levels of mRNA*

P{hsp83-AtSPO11-1 cDNA, A5-1}	3.40 ± 0.40


Parameter	c-MYC Nuclear Expression	Significance

ADA3 Nuclear Expression	Low No (%)	High No.(%)	x2	p value

Low No(%)	172 (49.1)	178 (50.9)	23.79	<0.0001

High No(%)	69 (29.0)	169 (71.3)

Parameter	c-MYC Nuclear Expression

ADA3 Nuclear Expression	Low No (%)	High No.(%)

Low No(%)	172 (49.1)	178 (50.9)

High No(%)	69 (29.0)	169 (71.3)


Mycobacterium smegmatis	Fold change	P-value	Gene name	Ortholog in Mtb	Annotated function

MSMEG_5576	3.4	2.2E-02	–	–	d-mannonate oxidoreductase

MSMEG_4920	4.9*	7.9E-04	fadA4	Rv1323	Acetyl-CoA acetyltransferase

MSMEG_4718	−1.8*	4.8E-01	bkaR	Rv2506	TetR transcriptional regulator (bkaR)*

MSMEG_4717	9.0*	3.7E-05	accD1	Rv2502c	Acetyl/propionyl-coenzyme A carboxylase (β subunit)

MSMEG_4716	15.0	1.5E-05	accA1	Rv2501c	Acetyl/propionyl-coenzyme A carboxylase (α subunit)

MSMEG_4715	13.7	5.8E-06	fadE19	Rv2500c	Acyl-CoA dehydrogenase

MSMEG_4714	9.5	1.1E-04	Rv2499c	Rv2499c	Hydratase

MSMEG_4713	16.5	4.6E-06	citE	Rv2498c	HpcH/HpaI aldolase/citrate lyase family protein

MSMEG_4712	8.4	1.1E-04	bkdA	Rv2497c	Part of branched-chain keto-acid dehydrogenase complex†

MSMEG_4711	3.3	3.3E-02	bkdB	Rv2496c	Part of branched-chain keto-acid dehydrogenase complex*

MSMEG_4710	1.8	4.9E-01	bkdC	Rv2495c	Part of branched-chain keto-acid dehydrogenase complex*

MSMEG_4005	−3.2	2.5E-02	–	–	Calcium-binding protein

MSMEG_2080	3.1	3.3E-02	fadE23	Rv3140	Putative acyl-CoA dehydrogenase

MSMEG_1885	3.3	2.2E-02	Rv3230c	Rv3230c	Iron–sulphur cluster binding domain protein

MSMEG_1548	3.0	4.3E-02	–	–	Dehydratase (propanediol utilization)

MSMEG_1543	3.2	2.3E-02	Rv0458	Rv0458	EPTC-Inducible aldehyde dehydrogenase

MSMEG_0881	−3.4	2.2E-02	–	–	Hypothetical protein

MSMEG_0066	3.3	2.2E-02	esxA	Rv3875	Early secretory antigenic target

Mycobacterium smegmatis

MSMEG_5576

MSMEG_4920

MSMEG_4718

MSMEG_4717

MSMEG_4716

MSMEG_4715

MSMEG_4714

MSMEG_4713

MSMEG_4712

MSMEG_4711

MSMEG_4710

MSMEG_4005

MSMEG_2080

MSMEG_1885

MSMEG_1548

MSMEG_1543

MSMEG_0881

MSMEG_0066

Fold change	P-value	Gene name	Ortholog in Mtb	Annotated function

3.4	2.2E-02	–	–	d-mannonate oxidoreductase

4.9*	7.9E-04	fadA4	Rv1323	Acetyl-CoA acetyltransferase

−1.8*	4.8E-01	bkaR	Rv2506	TetR transcriptional regulator (bkaR)*

9.0*	3.7E-05	accD1	Rv2502c	Acetyl/propionyl-coenzyme A carboxylase (β subunit)

15.0	1.5E-05	accA1	Rv2501c	Acetyl/propionyl-coenzyme A carboxylase (α subunit)

13.7	5.8E-06	fadE19	Rv2500c	Acyl-CoA dehydrogenase

9.5	1.1E-04	Rv2499c	Rv2499c	Hydratase

16.5	4.6E-06	citE	Rv2498c	HpcH/HpaI aldolase/citrate lyase family protein

8.4	1.1E-04	bkdA	Rv2497c	Part of branched-chain keto-acid dehydrogenase complex†

3.3	3.3E-02	bkdB	Rv2496c	Part of branched-chain keto-acid dehydrogenase complex*

1.8	4.9E-01	bkdC	Rv2495c	Part of branched-chain keto-acid dehydrogenase complex*

−3.2	2.5E-02	–	–	Calcium-binding protein

3.1	3.3E-02	fadE23	Rv3140	Putative acyl-CoA dehydrogenase

3.3	2.2E-02	Rv3230c	Rv3230c	Iron–sulphur cluster binding domain protein

3.0	4.3E-02	–	–	Dehydratase (propanediol utilization)

3.2	2.3E-02	Rv0458	Rv0458	EPTC-Inducible aldehyde dehydrogenase

−3.4	2.2E-02	–	–	Hypothetical protein

3.3	2.2E-02	esxA	Rv3875	Early secretory antigenic target